{"study_id": 104436, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to examine the renal protective efficacy of telbivudine (not Alanine) in hepatitis B virus-infected patients after living donor liver transplant.", "results_summary": "The study found that telbivudine improved renal function, with significant improvements in estimated glomerular filtration rates after 9 months and creatinine levels after 12 months compared to entecavir.", "population_specificity": "Hepatitis B virus-infected patients after living donor liver transplant.", "effective_dosage": "Telbivudine 600 mg once per day.", "study_duration": "At least 12 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:20.538643+00:00"}
{"study_id": 104437, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to outline the clinical significance of abnormal liver chemistries, particularly serum alanine aminotransferase (ALT), in diagnosing and evaluating liver diseases.", "results_summary": "The abstract highlights that elevated ALT levels are associated with increased liver-related mortality and provides reference ranges for healthy ALT levels. It also details the diagnostic approach for hepatocellular injury and cholestatic injury, including testing for various liver diseases.", "population_specificity": "Clinicians and patients with abnormal liver chemistries.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:22.198007+00:00"}
{"study_id": 104439, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of phlebotomy on insulin resistance, liver enzymes, and lipid profiles in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Phlebotomy reduced insulin resistance (HOMA-IR), lowered alanine aminotransferase and triglyceride levels, and increased high-density cholesterol levels in NAFLD patients.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:22.704253+00:00"}
{"study_id": 104441, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to determine the optimal dose, safety, and effectiveness of dual anti-angiogenic therapy with sorafenib and bevacizumab in patients with advanced HCC, not specifically focused on Alanine.", "results_summary": "The study reported dose-limiting toxicities including alanine/aspartate aminotransferase increase, but no specific results regarding Alanine's effects were highlighted.", "population_specificity": "Patients with locally advanced or metastatic HCC not amenable for surgery or liver transplant.", "effective_dosage": "Not specified for Alanine.", "study_duration": "28-day cycles.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:23.517997+00:00"}
{"study_id": 104440, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine if early 6-MMPR concentrations could predict hepatotoxicity (measured by alanine aminotransaminase elevations) in IBD patients starting thiopurine treatment.", "results_summary": "Elevated 6-MMPR concentrations at one week predicted hepatotoxicity in over 80% of cases, with age, gender, and BMI as additional risk factors. Hepatotoxicity occurred in 17% of patients within 20 weeks.", "population_specificity": "270 IBD patients initiating thiopurine treatment in a Dutch randomized-controlled trial.", "effective_dosage": "Not specified", "study_duration": "20 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:23.620426+00:00"}
{"study_id": 104438, "supplement_id": 863, "safety_score": "70", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of combining plitidepsin with sorafenib or gemcitabine in advanced cancer and lymphoma patients, including monitoring alanine aminotransferase (ALT) levels as a marker of liver toxicity.", "results_summary": "The study found manageable safety profiles for both combinations, with mild adverse events and rare grade 4 toxicities. Disease stabilization was observed in some patients, and objective responses were noted in heavily pretreated lymphoma patients receiving gemcitabine/plitidepsin.", "population_specificity": "Advanced cancer and lymphoma patients.", "effective_dosage": "Plitidepsin (1.8\u20133.0 mg/m\u00b2, days 1, 8, 15, q4wk); sorafenib (200\u2013400 mg twice daily); gemcitabine (750\u20131000 mg/m\u00b2, days 1, 8, 15, q4wk).", "study_duration": "Treatment cycles repeated every 4 weeks (q4wk).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:24.488794+00:00"}
{"study_id": 104442, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare long-term survival and immediate postoperative liver function in early gastric cancer patients with liver cirrhosis undergoing laparoscopic versus open distal gastrectomy.", "results_summary": "The study found no significant differences in liver function markers (including alanine aminotransferase) or long-term survival between the two surgical approaches, concluding that laparoscopic distal gastrectomy is a safe alternative to open surgery for these patients.", "population_specificity": "Early gastric cancer patients with liver cirrhosis (Child A classification)", "effective_dosage": "Not applicable", "study_duration": "Retrospective study covering procedures from January 2005 to April 2013", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:26.313003+00:00"}
{"study_id": 104444, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to describe the pharmacokinetics of ceritinib and evaluate covariate effects on systemic exposure at its label dose (750 mg orally once daily).", "results_summary": "The study described ceritinib concentration-time data using a 1-compartment model with delayed first-order absorption and time-dependent elimination. The apparent clearance at steady state was analyzed.", "population_specificity": "ALK-positive advanced non-small cell lung cancer patients previously treated with crizotinib.", "effective_dosage": "750 mg orally once daily", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:27.821243+00:00"}
{"study_id": 104443, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to determine whether maraviroc-containing regimens increased hepatotoxicity, specifically focusing on Grade 3/4 alanine aminotransferase (ALT) abnormalities and liver fibrosis in HIV-1 patients coinfected with HBV and/or HCV.", "results_summary": "The study found no significant increase in hepatotoxicity with maraviroc, with similar rates of Grade 3/4 ALT abnormalities between maraviroc and placebo groups. Some evidence suggested potential beneficial effects on liver fibrosis in the maraviroc group, though further investigation is needed.", "population_specificity": "HIV-1 patients coinfected with HBV and/or HCV.", "effective_dosage": "Maraviroc twice daily (specific dosage not mentioned).", "study_duration": "144 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:28.111542+00:00"}
{"study_id": 104445, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety and efficacy of nasobiliary drainage (NBD) in patients with benign recurrent intrahepatic cholestasis (BRIC) refractory to medical therapy, including its impact on biomarkers like alanine aminotransferase.", "results_summary": "NBD significantly improved biomarkers of cholestasis, including alanine aminotransferase, within 3 days and prolonged clinical remission in BRIC patients. Post-procedure complications were rare, with only one case of pancreatitis reported.", "population_specificity": "33 patients with BRIC (43% female), refractory to standard medical therapy.", "effective_dosage": "Not specified", "study_duration": "Median duration of NBD was 17 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.430152+00:00"}
{"study_id": 104446, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to assess the effectiveness of a diet based on Iranian traditional medicine (ITM) and current dietary recommendations in improving liver function in cirrhotic patients, including the impact on alanine aminotransferase (AST).", "results_summary": "The dietary intervention led to a significant decrease in AST (p=0.04) in the weight loss group and improved serum albumin in the weight gain group (p=0.02). ITM recommendations showed benefits for cirrhotic patients in both weight reduction and weight gain contexts.", "population_specificity": "57 subjects with class A or B cirrhosis in Tehran, Iran.", "effective_dosage": "Not specified", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.788082+00:00"}
{"study_id": 104447, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the predictive ability of tumor genomic LOH for response to rucaparib in patients with ovarian carcinoma, not specifically to evaluate alanine.", "results_summary": "The study found that elevations in alanine aminotransferase or aspartate aminotransferase were among the most common grade 3 or worse treatment-emergent adverse events (12% of patients). No specific effects or benefits of alanine were reported.", "population_specificity": "Patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma.", "effective_dosage": "Not applicable (alanine was not a focus of the study).", "study_duration": "Median duration of treatment was 5.7 months (IQR 2.8-10.1).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:31.972212+00:00"}
{"study_id": 104448, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize HIV/HCV co-infected children, adolescents, and young adults in Europe regarding HCV genotype, clinical status, and treatment outcomes, including liver disease progression.", "results_summary": "The study found that 55% of patients had elevated alanine aminotransferase (>40 IU/l), indicating liver inflammation, and 12% of those with transient elastography had significant liver stiffness (>9 kPa), associated with HCV infection duration. Liver biopsies in a subset revealed bridging fibrosis or cirrhosis in some cases.", "population_specificity": "Children, adolescents, and young adults (aged >18 months to <25 years) with vertically or childhood-acquired HIV/HCV co-infection in Europe.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:32.871122+00:00"}
{"study_id": 104449, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the clinical efficacy and side effects of nebulized budesonide versus systemic methylprednisolone in treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD), not specifically focused on Alanine.", "results_summary": "The study found no significant differences in clinical outcomes between the two treatments, but the budesonide group had fewer adverse events. Alanine aminotransferase levels were measured but not discussed in the context of Alanine's effects.", "population_specificity": "410 AECOPD patients across 10 hospitals.", "effective_dosage": "Not applicable (study did not focus on Alanine supplementation).", "study_duration": "Not specified (study duration not mentioned in the abstract).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:33.198440+00:00"}
{"study_id": 104450, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were attempting to determine the safety and efficacy of allogeneic CD19 CAR-T cells and mobilized PBSCs in elderly patients with relapsed and refractory ALL, including monitoring alanine transaminase levels as part of safety assessments.", "results_summary": "The study observed transient elevations in serum alanine transaminase and other liver enzymes, which were reversible after immunosuppressive therapy, suggesting potential liver-related complications from the treatment. The co-infusion approach achieved full donor engraftment and undetectable minimal residual disease.", "population_specificity": "Elderly patients (71-year-old female) with relapsed and refractory acute lymphoblastic leukemia (ALL).", "effective_dosage": "Not specified", "study_duration": "Observations were made from days 14 to 18 post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.302634+00:00"}
{"study_id": 104451, "supplement_id": 863, "safety_score": "85", "efficacy_score": 70, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 (a plasma-derived apoA-I) in patients with recent acute myocardial infarction.", "results_summary": "CSL112 was well-tolerated with no significant alterations in liver or kidney function, and it enhanced cholesterol efflux similarly to results seen in stable coronary artery disease patients. The risk of major adverse cardiovascular events was similar across treatment groups.", "population_specificity": "Patients with recent acute myocardial infarction, stratified by renal function.", "effective_dosage": "2 g or 6 g apoA-I per dose, administered weekly.", "study_duration": "4 consecutive weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.086623+00:00"}
{"study_id": 104452, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the association between chronic HBV infection and preterm birth (PTB) in pregnant women with normal alanine aminotransferase (ALT) levels.", "results_summary": "The study found no significant association between HBV carrier status and PTB incidence in their cohort (RR 0.98, 95% CI 0.71-1.37), but a meta-analysis including their data showed a significant association (pooled RR 1.26, 95% CI 1.19-1.33).", "population_specificity": "Pregnant women (20,498 total, 497 HBV carriers and 20,001 non-HBV controls) with normal ALT levels.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.534612+00:00"}
{"study_id": 104455, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the benefits and risks of SGLT2 inhibitors for type 2 diabetes.", "results_summary": "The study does not report findings on Alanine.", "population_specificity": "Patients with type 2 diabetes.", "effective_dosage": "Not applicable.", "study_duration": "Not applicable.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:39.214966+00:00"}
{"study_id": 104453, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate changes in liver function and clinical outcomes following stem cell transplantation in patients with liver disease, including the impact on serum alanine aminotransferase levels.", "results_summary": "The study found that serum alanine aminotransferase levels notably decreased at 1, 3, 4, 12, 24, and 48 weeks after stem cell transplantation, indicating improved liver function. Other liver function indices, such as serum albumin, aspartate aminotransferase, total bilirubin, and prothrombin time, also showed significant improvements.", "population_specificity": "Patients with liver diseases undergoing stem cell transplantation.", "effective_dosage": "Not specified", "study_duration": "Follow-up periods ranged from 1 to 48 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:40.037359+00:00"}
{"study_id": 104454, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety, tolerability, and efficacy of brigatinib, an ALK inhibitor, in patients with advanced malignancies, particularly ALK-rearranged NSCLC.", "results_summary": "The study found that brigatinib showed promising clinical activity in ALK-rearranged NSCLC patients, with objective responses observed in both crizotinib-treated and crizotinib-naive patients. Common adverse events included increased lipase concentration, dyspnoea, and hypertension, with some serious events reported.", "population_specificity": "Patients aged 18+ with advanced malignancies, including ALK-rearranged NSCLC, refractory to available therapies or without curative treatments.", "effective_dosage": "30-300 mg daily (phase 1); 90 mg once daily, 180 mg once daily, or 180 mg with a 7-day lead-in at 90 mg (phase 2).", "study_duration": "Ongoing study (enrollment from Sept 20, 2011, to July 8, 2014).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:41.590914+00:00"}
{"study_id": 104457, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the activity of cabozantinib in patients with RET-rearranged lung cancers, not specifically Alanine.", "results_summary": "The study found that cabozantinib produced a 28% overall response rate in patients with RET-rearranged lung cancers, with common grade 3 adverse events including increased alanine aminotransferase in 8% of patients.", "population_specificity": "Patients with metastatic or unresectable RET-rearranged lung adenocarcinomas.", "effective_dosage": "60 mg of cabozantinib orally per day.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.669178+00:00"}
{"study_id": 104456, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of sitagliptin (not Alanine) for treating Chinese patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Sitagliptin was more effective than diet and exercise in reducing hemoglobin A1c and fasting plasma glucose levels, but no significant changes were observed in alanine aminotransferase levels. The study concluded sitagliptin is safe and effective for T2DM with NAFLD.", "population_specificity": "72 Chinese patients with T2DM and NAFLD.", "effective_dosage": "Not specified for Alanine (study focused on sitagliptin).", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.990942+00:00"}
{"study_id": 104462, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers reviewed the molecular mechanisms of CSF secretion by the choroid plexus epithelium and explored potential drug targets for hydrocephalus treatment.", "results_summary": "The study discussed the role of increased CSF production in hydrocephalus and suggested investigating ion channels and transporters for pharmacotherapeutic intervention, but did not specifically address Alanine.", "population_specificity": "Not specified (focus on hydrocephalus pathophysiology and choroid plexus function).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.682377+00:00"}
{"study_id": 104461, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the performance of the gamma-glutamyl transpeptidase-to-platelet ratio (GPR) model for diagnosing liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA levels.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects, as the focus was on comparing GPR to other diagnostic models (APRI and Fib-4) for liver fibrosis and cirrhosis in HBV patients.", "population_specificity": "HBeAg-positive chronic HBV infection patients with high HBV DNA (\u22655 log) in West Africa.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.321629+00:00"}
{"study_id": 104464, "supplement_id": 863, "safety_score": "80", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of pradigastat, a DGAT-1 inhibitor, in reducing serum viral RNA and alanine aminotransferase levels in patients with HCV infection.", "results_summary": "In vitro, pradigastat significantly reduced virus production, but the clinical study showed no significant change in serum viral RNA levels after 14 days of treatment. Pradigastat was safe and well-tolerated, with no hepatic adverse events reported.", "population_specificity": "32 patients with HCV infection (26 treated with pradigastat, 6 with placebo).", "effective_dosage": "Once daily for 14 days (specific dosage not mentioned).", "study_duration": "14 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.334898+00:00"}
{"study_id": 104463, "supplement_id": 863, "safety_score": "65", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to establish the maximum tolerated dose (MTD) and evaluate the safety and efficacy of buparlisib (BKM120), a PI3K inhibitor, in Chinese patients with advanced solid tumors, with a focus on adverse events including alanine aminotransferase (ALT) increase.", "results_summary": "The study found that buparlisib had an acceptable safety profile, with hyperglycemia and ALT/AST increases as common adverse events. The best response was stable disease in 31% of patients, indicating limited efficacy.", "population_specificity": "Chinese patients with advanced solid tumors (lung, breast, or head and neck cancers) who had received \u22652 prior lines of antineoplastic therapy.", "effective_dosage": "80 mg or 100 mg daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:50.354078+00:00"}
{"study_id": 104467, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the relationship between the aspartate aminotransferase-to-alanine aminotransferase ratio (AAR) and mortality risk in patients with type 2 diabetes.", "results_summary": "An increased AAR was significantly associated with higher risks of all-cause and cardiovascular mortality in type 2 diabetic patients, independent of other clinical risk factors. The study suggests that AAR may reflect systemic derangements beyond liver damage.", "population_specificity": "2529 type 2 diabetic outpatients", "effective_dosage": "Not specified", "study_duration": "6-year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:50.661568+00:00"}
{"study_id": 104465, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine whether cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD, as measured by improvements in liver histology and serum aminotransferase levels.", "results_summary": "CBDR did not significantly improve the primary outcome of liver histology compared to placebo, but it significantly reduced serum alanine aminotransferase and aspartate aminotransferase levels and lobular inflammation. A post hoc analysis showed histologic improvement in children weighing \u226465 kg.", "population_specificity": "Children with NAFLD activity scores of 4 or higher.", "effective_dosage": "300 mg (\u226465 kg), 375 mg (>65 to 80 kg), or 450 mg (>80 kg) twice daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:51.102172+00:00"}
{"study_id": 104466, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, efficacy, and pharmacokinetics of ritonavir-boosted danoprevir plus peginterferon alfa-2a/ribavirin in treatment-naive Asian patients with chronic hepatitis C virus genotype 1 infection.", "results_summary": "The study found high sustained virologic response rates (>90%) in noncirrhotic and cirrhotic Asian patients with genotype 1b infection, with no Grade 3/4 alanine aminotransferase elevations reported. The treatment was well tolerated, with no withdrawals due to safety reasons.", "population_specificity": "Treatment-naive Asian patients with chronic hepatitis C virus genotype 1 infection from Taiwan, Thailand, and Korea.", "effective_dosage": "Not specified", "study_duration": "12 weeks for noncirrhotic patients, 24 weeks for cirrhotic patients", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:51.687046+00:00"}
{"study_id": 104469, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the safety and feasibility of normothermic ex vivo liver perfusion (NEVLP) using Steen solution versus cold storage (CS) for liver transplantation.", "results_summary": "NEVLP with Steen solution showed comparable outcomes to CS, with no significant differences in graft function, complications, or patient survival. The study concluded that NEVLP using Steen solution is safe and feasible for liver transplantation.", "population_specificity": "Patients undergoing liver transplantation.", "effective_dosage": "Not applicable (perfusion solution used, not a dosage).", "study_duration": "Perfusion duration ranged from 340 to 580 minutes.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.085941+00:00"}
{"study_id": 104468, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify potential biomarkers, including alanine aminotransferase (ALT), for amoxicillin/clavulanate-induced liver injury (AC-DILI) using multi-omics approaches.", "results_summary": "The study found that liver-specific microRNA-122 (miR-122) levels increased before and correlated with ALT elevation, suggesting its potential as an early marker for AC-DILI. Urinary metabolites and lymphocyte proliferation also showed significant changes, indicating sequential metabolic and immune responses to the drug.", "population_specificity": "32 healthy subjects", "effective_dosage": "Not specified for alanine (study focused on amoxicillin/clavulanate administration)", "study_duration": "14 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.206515+00:00"}
{"study_id": 104470, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to highlight the challenges in HBV testing, diagnosis, and treatment in low-income and middle-income countries, including the role of alanine aminotransferase levels in determining antiviral therapy indications.", "results_summary": "The study found that HBV testing in these regions is often limited to basic measures like alanine aminotransferase levels due to resource constraints, leading to delays and loss to follow-up. Antiviral therapy utilization is hindered by cost and availability, despite its potential to reduce cirrhosis and hepatocellular carcinoma.", "population_specificity": "Low-income and middle-income countries, particularly in East Asia and sub-Saharan Africa.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:56.855979+00:00"}
{"study_id": 104471, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to identify the role of myristoylated alanine-rich C-kinase substrate (MARCKS) in the activation of cancer-associated fibroblasts (CAFs) and its impact on ovarian cancer progression.", "results_summary": "The study found that MARCKS was highly expressed in ovarian stroma and essential for CAF differentiation and tumor-promoting functions. Suppressing MARCKS reduced CAF activation, impaired tumor cell growth in models, and was linked to poor patient survival in epithelial ovarian cancer (EOC).", "population_specificity": "Patients with epithelial ovarian cancer (EOC) and murine xenograft models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:58.640913+00:00"}
{"study_id": 104473, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the potential of serum Pro-C3 levels, including their association with alanine aminotransferase (ALT) reductions, as biomarkers for identifying patients likely to benefit from antifibrotic treatments like balaglitazone.", "results_summary": "The study found that subjects with the highest Pro-C3 levels responded to balaglitazone with reductions in ALT and Pro-C3 levels, along with improved insulin sensitivity and lipid profile. Elevated Pro-C3 levels were indicative of active fibrogenesis and identified patients most likely to benefit from treatment.", "population_specificity": "Patients with late-stage Type 2 diabetes (BALLET study) and advanced hepatitis C (farglitazar study).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:59.837012+00:00"}
{"study_id": 104472, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and feasibility of neoadjuvant intraprostatic injections of Ad-REIC (adenovirus vector carrying the human REIC/Dkk-3 gene) in high-risk localized prostate cancer patients.", "results_summary": "The study confirmed the safety of therapeutic interventions with escalating doses of Ad-REIC, but efficacy results regarding Alanine were not addressed in the provided abstract.", "population_specificity": "Patients with high-risk localized prostate cancer and a recurrence probability of 35% or more within 5 years post-radical prostatectomy.", "effective_dosage": "Initially planned three escalating doses (1.0 \u00d7 10^10, 1.0 \u00d7 10^11, and 1.0 \u00d7 10^12 viral particles), but only two injections at 2-week intervals were mentioned.", "study_duration": "6 weeks (two injections at 2-week intervals, followed by radical prostatectomy).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:00.793984+00:00"}
{"study_id": 104474, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the tolerability, safety, and pharmacokinetics of nivolumab combined with standard chemotherapy in patients with advanced NSCLC, with incidental mention of alanine aminotransferase increase as a dose-limiting toxicity.", "results_summary": "The study found that the combination of nivolumab and chemotherapy was well tolerated, with one patient in arm A experiencing increased alanine aminotransferase as a dose-limiting toxicity. No further specific findings regarding alanine were reported.", "population_specificity": "Patients with advanced non-small-cell lung cancer (stage IIIB without indication for definitive radiotherapy, stage IV, or recurrent NSCLC).", "effective_dosage": "Not specified for alanine (nivolumab dosage was 10 mg/kg).", "study_duration": "Up to four or six cycles of chemotherapy, followed by maintenance therapy until disease progression or unacceptable toxicity.", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:01.465994+00:00"}
{"study_id": 104475, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate liver injury associated with quetiapine XR in very heavy drinking alcohol-dependent patients, focusing on alanine aminotransaminase (ALT) levels.", "results_summary": "The study found no significant exacerbation of liver injury in patients with pre-existing liver injury treated with quetiapine XR. New liver injury cases in patients without pre-existing injury were rare and mild.", "population_specificity": "Very heavy drinking alcohol-dependent patients aged 18-65.", "effective_dosage": "400 mg/day (dose-escalated over 4 weeks).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:01.708274+00:00"}
{"study_id": 104476, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the efficacy and safety of erlotinib for advanced hepatocellular carcinoma (HCC), not specifically studying alanine.", "results_summary": "The abstract mentions increased alanine and aspartate transaminases (7.3%) as a frequent grade 3/4 toxicity, but does not evaluate alanine's effects.", "population_specificity": "Patients with advanced hepatocellular carcinoma (HCC).", "effective_dosage": "Not mentioned for alanine.", "study_duration": "Not mentioned for alanine.", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:02.050472+00:00"}
{"study_id": 104460, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of two combined therapies (LAM+ADV and LdT+ADV) for chronic hepatitis B infection, including their effects on renal function and alanine aminotransferase (ALT) levels.", "results_summary": "Both therapies showed similar anti-HBV efficacy (DNA undetectable rate, ALT normalization, HBeAg seroconversion) and stable/improved renal function, though LdT+ADV had higher eGFR fluctuations and serum creatine kinase levels.", "population_specificity": "171 patients with chronic hepatitis B infection (110 on LAM+ADV, 60 on LdT+ADV).", "effective_dosage": "Not specified", "study_duration": "48 to 240 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:07.027634+00:00"}
{"study_id": 104477, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the clinicopathologic features of patients with common bile duct (CBD) stones and high aminotransferase levels, including alanine aminotransferase, to differentiate liver disease from gallstone-related conditions.", "results_summary": "The study found that patients with CBD stones and high aminotransferase levels (gallstone hepatitis group) were younger, had narrower CBDs, and experienced more severe, short-lasting abdominal pain compared to controls, with liver biopsies showing only mild inflammation. These findings suggest that sudden CBD pressure increases due to gallstone migration may cause transient liver enzyme elevations without significant liver damage.", "population_specificity": "882 patients diagnosed with CBD stones via endoscopic retrograde cholangiopancreatography (ERCP), including 38 with aminotransferase levels >400 IU/L (gallstone hepatitis group) and 116 with normal aminotransferase levels (control group).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:07.411799+00:00"}
{"study_id": 104478, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and tolerability of fingolimod in Italian patients with relapsing-remitting multiple sclerosis (RRMS), not specifically Alanine.", "results_summary": "The study found that fingolimod was generally safe and well-tolerated, with adverse events reported in 35.4% of patients and serious adverse events in 2.9%. Increased alanine aminotransferase levels were reported as an adverse event in 1.0% of patients.", "population_specificity": "Italian patients with relapsing-remitting multiple sclerosis (RRMS) with no suitable alternative treatment option.", "effective_dosage": "0.5 mg fingolimod (not specific to Alanine).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:07.829422+00:00"}
{"study_id": 104479, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of a prime-boost vaccination regimen involving rV-CEA(6D)-TRICOM and rF-CEA(6D)-TRICOM, combined with GM-CSF and IFN-\u03b1, in patients with CEA-expressing cancers.", "results_summary": "The study found no partial responses, but eight patients had stable disease for \u22653 months. IFN-\u03b1 administration was associated with improved survival, and 42% of patients developed CEA-specific T cell responses.", "population_specificity": "Patients with CEA-expressing cancers (mean age 59.8 years).", "effective_dosage": "rV-CEA(6D)-TRICOM on day 1, GM-CSF on days 1-4, and IFN-\u03b1-2b thrice weekly in varying cycles.", "study_duration": "Cycles 1-4, with follow-up for progression-free and overall survival.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:09.421428+00:00"}
{"study_id": 104480, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review literature on acute liver damage (ALD) in Graves' ophthalmopathy patients receiving intravenous glucocorticoids, focusing on alanine aminotransferase (ALT) levels.", "results_summary": "ALD (ALT >300 U/L) was reported in 17 cases, with half diagnosed as autoimmune hepatitis and others suspected of methylprednisolone-induced hepatotoxicity; four fatal cases occurred with high cumulative doses (>8 g). The overall ALD risk is low (~1%) but increases with higher doses.", "population_specificity": "Patients with Graves' ophthalmopathy receiving intravenous glucocorticoids.", "effective_dosage": "Single dose >0.5 g and cumulative dose >8.5 g methylprednisolone.", "study_duration": "Monitoring during treatment and up to 6 months post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:10.474208+00:00"}
{"study_id": 104481, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to analyze the effect of specific genetic polymorphisms on liver and bone marrow toxicity related to methotrexate (MTX) use, including the role of serum alanine aminotransferase (GPT) levels as a marker of liver toxicity.", "results_summary": "The study found that the CC genotype of rs1045642 in ABCB1 was associated with significantly higher GPT levels (indicating liver toxicity) in patients taking MTX. Additionally, the G allele of rs1544105 in FPGS was linked to lower leukocyte, hemoglobin, and platelet levels, suggesting hematologic toxicity.", "population_specificity": "350 patients from the PEARL (Princesa Early Arthritis Register Longitudinal) study, including 732 visits with MTX and 683 without MTX.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:10.952913+00:00"}
{"study_id": 104483, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the diagnostic performance of 2D SWE and RTE for assessing liver fibrosis in patients with Chronic Hepatitis B (CHB) and evaluate the influence of inflammation on stiffness measurements.", "results_summary": "The study found that 2D SWE was more accurate than RTE in diagnosing significant fibrosis and cirrhosis in CHB patients, though its measurements were more affected by inflammation fluctuations. Both techniques showed increased stiffness values with higher fibrosis and inflammation grades.", "population_specificity": "437 patients with Chronic Hepatitis B (CHB) meeting inclusion criteria.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:11.340886+00:00"}
{"study_id": 104482, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC) who had progressed after previous EGFR tyrosine-kinase inhibitor therapy.", "results_summary": "The study found that osimertinib showed clinical activity with manageable side-effects, with 70% of patients achieving an objective response. Common adverse events included pulmonary embolism, prolonged QT interval, and increased alanine aminotransferase, with few serious adverse events reported.", "population_specificity": "Patients aged at least 18 years with centrally confirmed EGFR Thr790Met-positive mutations, locally advanced or metastatic NSCLC who progressed on previous EGFR tyrosine-kinase inhibitor therapy.", "effective_dosage": "80 mg orally once daily", "study_duration": "Median duration of follow-up was 13.0 months (IQR 7.6-14.2)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:12.620242+00:00"}
{"study_id": 104486, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the effects of cabergoline on blood glucose levels in patients with type 2 diabetes mellitus, not specifically Alanine.", "results_summary": "The abstract does not report any findings related to Alanine's effects.", "population_specificity": "Patients with type 2 diabetes mellitus.", "effective_dosage": "Not available (study focused on cabergoline, not Alanine).", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:15.135394+00:00"}
{"study_id": 104485, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the impact of telbivudine treatment on HBV mother-to-child transmission and neonatal outcomes, including alanine transaminase levels.", "results_summary": "Telbivudine treatment reduced HBV MTCT rates without affecting pregnancy or neonatal outcomes. Discontinuing telbivudine postpartum did not impact hepatic function but increased HBV DNA levels.", "population_specificity": "HBV-infected pregnant women and their infants.", "effective_dosage": "Not specified", "study_duration": "Treatment began before 14 weeks or between 14-28 weeks of gestation, with follow-up until 7 months postpartum.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:16.337209+00:00"}
{"study_id": 104484, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) in improving pruritus, liver function, and maternal/fetal outcomes in patients with intrahepatic cholestasis of pregnancy (ICP).", "results_summary": "UDCA significantly improved pruritus, reduced serum alanine aminotransferase (ALT) and bile acid levels, and decreased adverse maternal and fetal outcomes, including premature births, fetal distress, and respiratory distress syndrome. No significant adverse effects were reported except for nausea and emesis.", "population_specificity": "Pregnant women with intrahepatic cholestasis of pregnancy (ICP).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.158689+00:00"}
{"study_id": 104489, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention Alanine or its effects.", "results_summary": "The abstract does not discuss Alanine or its effects.", "population_specificity": "The abstract focuses on hepatitis E patients, not Alanine.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.753045+00:00"}
{"study_id": 104487, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether metformin therapy alters circulating alanine concentrations and whether these changes are linked to weight, fat mass, or insulin resistance.", "results_summary": "The study found that alanine concentrations significantly increased in the metformin-treated group compared to placebo, with a rise of 42 \u03bcmol/l (P<0.0001). These changes were independent of weight, fat mass, or insulin resistance.", "population_specificity": "173 individuals without Type 2 diabetes but with coronary disease.", "effective_dosage": "Not specified (metformin dosage not detailed in abstract).", "study_duration": "18 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.691737+00:00"}
{"study_id": 104490, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the clinical outcomes of culture-negative pyogenic liver abscess (CNPLA) and Klebsiella pneumoniae pyogenic liver abscess (KPPLA) patients, including differences in laboratory markers such as alanine aminotransferase.", "results_summary": "The study found that KPPLA patients had elevated alanine aminotransferase levels compared to CNPLA patients, but there was no difference in hospital stay or mortality between the two groups.", "population_specificity": "Patients with pyogenic liver abscess (CNPLA or KPPLA) admitted from January 2003 to December 2011.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:19.986197+00:00"}
{"study_id": 104491, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the long-term clinical outcomes of antiviral-na\u00efve chronic hepatitis B patients treated with entecavir (ETV) monotherapy versus lamivudine (LAM)-resistant patients receiving adefovir (ADV) add-on LAM combination treatment.", "results_summary": "The study found that antiviral-na\u00efve patients treated with ETV showed significantly greater reductions in serum HBV-DNA levels compared to those receiving ADV add-on LAM. Alanine aminotransferase normalization rates were higher in the ETV group (90.4% at 6 months) than in the ADV add-on LAM group (77.8% at 12 months).", "population_specificity": "Antiviral-na\u00efve chronic hepatitis B patients and LAM-resistant patients.", "effective_dosage": "0.5-mg ETV (initial therapy), ADV add-on LAM (rescue therapy).", "study_duration": "24 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:22.459047+00:00"}
{"study_id": 104492, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 52, "quality_score": 65, "study_goal": "The researchers aimed to investigate the clinical characteristics and treatment outcomes of Korean patients infected with genotype 6 hepatitis C virus (HCV), including the role of alanine transaminase levels.", "results_summary": "The study found that Korean patients with genotype 6 HCV had a median alanine transaminase level of 88 IU/mL, and treatment with peginterferon and ribavirin resulted in a 52% sustained virologic response rate. Longer treatment duration and rapid virologic response were associated with better outcomes.", "population_specificity": "Korean patients infected with genotype 6 HCV (n=32).", "effective_dosage": "Not specified for alanine transaminase; treatment involved peginterferon and ribavirin (dosages not detailed).", "study_duration": "Treatment durations varied (24 weeks and >48 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:24.701267+00:00"}
{"study_id": 104495, "supplement_id": 863, "safety_score": "70", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers evaluated the prevalence of hepatic and hematological adverse effects associated with long-term low-dose methotrexate (MTX) therapy in rheumatoid arthritis patients, including the impact on alanine transaminase levels.", "results_summary": "The study found a 6.37% frequency of raised alanine transaminase levels (\u22653-fold rise above normal), including two cases of biopsy-proven hepatic fibrosis. Severe anemia and leukopenia were observed in 5.4% and 4.4% of patients, respectively.", "population_specificity": "Rheumatoid arthritis patients in the Indian population taking \u226415 mg/week MTX for at least 2 years.", "effective_dosage": "\u226415 mg/week", "study_duration": "At least 2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:26.277720+00:00"}
{"study_id": 104494, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess whether basal insulin peglispro (BIL) was non-inferior to isophane insulin (NPH) in reducing HbA1c in insulin-na\u00efve patients with type 2 diabetes.", "results_summary": "BIL was non-inferior to NPH in reducing HbA1c, with greater reductions in fasting serum glucose and nocturnal hypoglycaemia rates, though mean alanine aminotransferase (ALT) increased with BIL treatment without evidence of severe hepatotoxicity.", "population_specificity": "Insulin-na\u00efve patients with type 2 diabetes.", "effective_dosage": "Not specified (bedtime or morning administration).", "study_duration": "26-week treatment period.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:26.392353+00:00"}
{"study_id": 104497, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of omega-3 polyunsaturated fatty acids (\u03c9-3 PUFA) in treating non-alcoholic fatty liver disease (NAFLD), with a focus on biomarkers like alanine aminotransferase (ALT).", "results_summary": "The study found that \u03c9-3 PUFA significantly improved ALT, total cholesterol, and triglyceride levels, with a tendency toward beneficial effects on other liver enzymes and lipids. The results were statistically significant for key outcomes, particularly in reducing triglycerides.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:28.596711+00:00"}
{"study_id": 104496, "supplement_id": 863, "safety_score": "70", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to determine the recommended phase 2 dose, safety, pharmacokinetics, and antitumor activity of oral ridaforolimus in children with advanced solid tumors, including its effects on alanine aminotransferase levels.", "results_summary": "The study found that ridaforolimus was generally well tolerated, with manageable grade 1-2 adverse events, including increased alanine aminotransferase. The recommended phase 2 dose was 33 mg/m2, and some patients showed stable disease.", "population_specificity": "Children aged 6 to <18 years with advanced solid tumors.", "effective_dosage": "22 mg/m2, 28 mg/m2, and 33 mg/m2, administered orally for 5 consecutive days/week in 28-day cycles.", "study_duration": "Until progression, unacceptable toxicity, or consent withdrawal (some patients received up to 46 cycles).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:29.356917+00:00"}
{"study_id": 104488, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the real-world effectiveness of sofosbuvir-based regimens in treating hepatitis C virus (HCV) among a vulnerable population.", "results_summary": "The study found high rates of sustained virologic response (SVR 12) in safety-net HCV-infected patients treated with sofosbuvir-based regimens, indicating effective HCV treatment in this population.", "population_specificity": "Vulnerable HCV-infected patients (median age 58, 60% male, 42% Caucasian, 72% genotype 1) in a safety-net healthcare system.", "effective_dosage": "Not specified (sofosbuvir-based regimens combined with other antivirals).", "study_duration": "12-24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:29.514511+00:00"}
{"study_id": 104498, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were evaluating the safety and clinical activity of linsitinib, an IGF-1R tyrosine kinase inhibitor, in relapsed small-cell lung cancer (SCLC) patients, not specifically Alanine.", "results_summary": "The study found that linsitinib was safe but showed no clinical activity in unselected, relapsed SCLC patients. Adverse events included thrombocytopenia, fatigue, and alanine aminotransferase/aspartate aminotransferase elevations.", "population_specificity": "Relapsed small-cell lung cancer (SCLC) patients.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:31.882570+00:00"}
{"study_id": 104493, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, efficacy, and metabolic effects of basal insulin peglispro (BIL), including its impact on alanine aminotransferase (ALT) levels and liver fat, compared to conventional insulin therapies.", "results_summary": "BIL demonstrated better glycemic control, reduced glucose variability, and lower nocturnal hypoglycemia rates compared to glargine and NPH insulins. However, it was associated with increased liver fat, triglycerides, and ALT levels, though without severe liver injury.", "population_specificity": "Patients with type 1 diabetes (T1D) and type 2 diabetes (T2D), including over 6000 participants in the IMAGINE-Phase 3 clinical trial program.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.133988+00:00"}
{"study_id": 104499, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the therapeutic effects of low-frequency phonophoresis with a Chinese herbal medicine (CHM) versus sodium diclofenac (SD) for knee osteoarthritis (KOA), including evaluating safety through laboratory tests such as alanine aminotransferase.", "results_summary": "The study found significant improvements in pain relief and physical function for both CHM and SD groups, with no significant differences between them. Safety assessments included monitoring alanine aminotransferase levels, but no specific adverse effects related to alanine were reported.", "population_specificity": "100 patients with knee osteoarthritis.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.311164+00:00"}
{"study_id": 104501, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the predictive value of liver disease markers, including alanine transaminase, for mortality in HIV-monoinfected and HIV/HCV-coinfected individuals.", "results_summary": "The study found that higher alanine transaminase (AST) levels were associated with increased mortality, particularly in HIV/HCV-coinfected individuals, but not significantly in HIV-monoinfected individuals. Lower serum albumin was also linked to higher mortality, with stronger associations in coinfected participants.", "population_specificity": "HIV-monoinfected (n=720) and HIV/HCV-coinfected (n=193) individuals.", "effective_dosage": "Not specified", "study_duration": "5-year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:35.103436+00:00"}
{"study_id": 104500, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether iron depletion via bloodletting combined with lifestyle and diet advice (LFDA) improves metabolic and hepatic outcomes, including alanine aminotransferase levels, in nondiabetic patients with dysmetabolic iron overload syndrome (DIOS).", "results_summary": "The study found no significant improvement in alanine aminotransferase levels (33 \u00b1 22 IU/L in the intervention group vs. 37 \u00b1 21 IU/L in controls, P = 0.10) or other metabolic and hepatic markers with iron depletion. Weight loss, rather than bloodletting, was associated with improved outcomes.", "population_specificity": "Nondiabetic DIOS patients with hepatic iron >50 \u03bcmol/g at MRI.", "effective_dosage": "Not specified (bloodletting volume: 4.9 \u00b1 1.6 L over the study period).", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:36.384566+00:00"}
{"study_id": 104502, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and safety of regorafenib and TAS-102 in patients with refractory metastatic colorectal cancer, not specifically focusing on Alanine.", "results_summary": "The study found that regorafenib and TAS-102 had similar efficacy but different toxicity profiles, with regorafenib causing more hand-foot syndrome and liver-related adverse events, while TAS-102 led to more hematologic toxicities. No significant differences in progression-free or overall survival were observed between the two treatments.", "population_specificity": "Patients with refractory metastatic colorectal cancer who had failed prior therapies including fluoropyrimidines, oxaliplatin, irinotecan, and anti-VEGF/EGFR antibodies.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:37.876220+00:00"}
{"study_id": 104503, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine whether tissue elastography (TE) could serve as an alternative to MRI T2* analysis for assessing hepatic iron overload in thalassemia major patients.", "results_summary": "TE liver stiffness measurements strongly correlated with MRI R2* values (r = 0.85) and effectively identified severe, moderate, and mild iron overload with high sensitivity and specificity. No correlation was found between TE results and serum ferritin levels.", "population_specificity": "154 thalassemia major patients (99 male; mean age 12 \u00b1 3.6 years) requiring chronic blood transfusion and iron chelator therapy.", "effective_dosage": "Not available", "study_duration": "Study conducted over 6 months (January 2015\u2013June 2015).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:39.287136+00:00"}
{"study_id": 104504, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to define the clinical, biochemical, and histologic features of liver injury caused by thiopurines (azathioprine and 6-mercaptopurine), including the role of alanine aminotransferase levels as a marker.", "results_summary": "The study found that thiopurine-induced liver injury typically presents as self-limited cholestatic hepatitis, with median alanine aminotransferase levels of 210 U/L at onset. Most cases resolved clinically, except for one patient with preexisting cirrhosis who required liver transplantation.", "population_specificity": "Patients with thiopurine-induced liver injury (median age 55 years, 68% female), primarily with inflammatory bowel disease (55%).", "effective_dosage": "Median thiopurine dose was 150 mg daily (range: 25\u2013300 mg).", "study_duration": "Median latency to liver injury onset was 75 days (range: 3\u20132584 days).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:41.917431+00:00"}
{"study_id": 104505, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine if \u03c9-3 fatty acid supplementation reduces chemotherapy-related toxicities, including effects on alanine aminotransferase levels.", "results_summary": "\u03c9-3-rich EN support reduced stomatitis frequency and showed hepatoprotective effects (lower aspartate aminotransferase and alanine aminotransferase levels) compared to \u03c9-3-poor EN, but did not significantly affect body weight or severe neutropenia.", "population_specificity": "61 patients undergoing neoadjuvant chemotherapy for esophageal cancer.", "effective_dosage": "900 mg \u03c9-3 fatty acids daily (\u03c9-3-rich group) vs. 250 mg (\u03c9-3-poor group).", "study_duration": "15 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:42.418282+00:00"}
{"study_id": 104507, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize the role of FoxA2 in mediating the therapeutic effects of biliary-committed progenitor cells during cholestatic liver injury.", "results_summary": "The study found that FoxA2, a definitive endoderm marker, plays a key role in biliary development and mediates the therapeutic effects of biliary-committed progenitor cells in cholestatic liver injury. Liver tissues and hepatic stellate cells from PSC and PBC patients were analyzed, and FoxA2 was shown to regulate cell differentiation and tissue regeneration.", "population_specificity": "Mice (BDL and MDR2 knockout models) and human liver tissues/HSCs from PSC and PBC patients.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.221385+00:00"}
{"study_id": 104506, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the accuracy of the AcetaSTAT immunoassay versus HPLC-EC in detecting acetaminophen protein adducts in patients with acute liver injury.", "results_summary": "AcetaSTAT demonstrated high sensitivity (100%) and specificity (86.2%) in identifying acetaminophen-associated acute liver injury, with strong concordance to HPLC-EC results. The assay correctly identified cases missed by initial clinical diagnosis in some instances.", "population_specificity": "Healthy individuals, patients without acetaminophen-associated acute liver injury, and patients with acetaminophen-associated acute liver injury from the Acute Liver Failure Study Group registry.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.801929+00:00"}
{"study_id": 104508, "supplement_id": 863, "safety_score": "75", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, preliminary efficacy, and pharmacokinetics of nintedanib in Japanese patients with advanced hepatocellular carcinoma and mild/moderate liver impairment.", "results_summary": "The study found that nintedanib had a manageable safety profile with no dose-limiting toxicities reported during cycle 1, and the maximum tolerated dose was 200 mg twice daily. Median time to progression was 2.8 months for mild liver impairment and 3.2 months for moderate liver impairment.", "population_specificity": "Japanese patients with advanced hepatocellular carcinoma and mild/moderate liver impairment.", "effective_dosage": "150 mg or 100 mg twice daily, escalating to 200 mg twice daily.", "study_duration": "Until disease progression or unacceptable adverse events (28-day cycles).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:44.237489+00:00"}
{"study_id": 104509, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the influence of luseogliflozin on HbA1c and hepatic function, including alanine aminotransferase (ALT) levels, in patients with type 2 diabetes, comparing those with normal versus elevated hepatic function parameters.", "results_summary": "Luseogliflozin significantly improved HbA1c and body weight in both groups and reduced AST, ALT, and \u03b3-GTP levels, suggesting it may alleviate hepatic impairment in type 2 diabetes patients.", "population_specificity": "Patients with type 2 diabetes, divided into normal and elevated hepatic function groups.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:45.141350+00:00"}
{"study_id": 104511, "supplement_id": 863, "safety_score": "60", "efficacy_score": 30, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the toxicity profile and maximum tolerated dose of plitidepsin combined with bevacizumab, including monitoring alanine aminotransferase increases as a safety measure.", "results_summary": "The study observed grade 2/3 alanine aminotransferase increases in some patients, indicating potential liver toxicity, but stable disease was the best clinical response achieved. No objective disease responses were noted.", "population_specificity": "Advanced cancer patients (colorectal, renal, and cervical cancer).", "effective_dosage": "Plitidepsin at 2.8 mg/m, 3.8 mg/m, and 4.8 mg/m with bevacizumab at 10 mg/kg, administered intravenously on days 1 and 15 of a 28-day cycle.", "study_duration": "Treatment cycles lasted 28 days, but exact total duration is unspecified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:48.819947+00:00"}
{"study_id": 104510, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the 2-year overall survival outcomes of nivolumab plus ipilimumab compared to ipilimumab alone in previously untreated advanced melanoma patients, with a focus on adverse events including increased alanine aminotransferase.", "results_summary": "The study found that 11% of patients in the nivolumab plus ipilimumab group experienced increased alanine aminotransferase as a grade 3-4 adverse event. No new treatment-related adverse events or deaths were reported in the updated analysis.", "population_specificity": "Patients aged 18+ with previously untreated, unresectable stage III or IV melanoma and an ECOG performance status of 0 or 1.", "effective_dosage": "Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks.", "study_duration": "Median follow-up of 24.5 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:49.170220+00:00"}
{"study_id": 104513, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the treatment outcomes of entecavir (ETV) in patients with hepatitis B decompensated cirrhosis, focusing on HBV-DNA loss, ALT normalization, and mortality rates.", "results_summary": "The meta-analysis found that ETV treatment led to higher HBV-DNA loss, normalized ALT levels, and reduced early mortality at 24 and 48 weeks, though no significant difference was observed in total mortality or HBeAg seroconversion.", "population_specificity": "Patients with hepatitis B decompensated cirrhosis (2040 participants across 26 studies).", "effective_dosage": "Not specified", "study_duration": "24 and 48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.618520+00:00"}
{"study_id": 104512, "supplement_id": 863, "safety_score": "65", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to investigate the efficacy and safety of circularly permuted TRAIL (CPT) as a single-agent therapy for patients with relapsed or refractory multiple myeloma (RRMM).", "results_summary": "The study found an overall response rate of 33.3%, including 1 near-complete response and 8 partial responses, with a clinical benefit rate of 48.1%. Common adverse events included fever, liver enzyme elevations, and blood cell count reductions, with 37.0% of patients experiencing grade 3-4 toxicity.", "population_specificity": "Patients with relapsed or refractory multiple myeloma (RRMM).", "effective_dosage": "2.5 mg/kg per day, intravenously, for 14 consecutive days per 21-day cycle.", "study_duration": "Treatment cycles were 21 days, with CPT administered for 14 days per cycle (total duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.670019+00:00"}
{"study_id": 104516, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify metabolic changes, including alanine levels, in patients undergoing bariatric surgery, particularly focusing on short-term and long-term effects up to one year post-surgery.", "results_summary": "The study found a significant decrease in alanine levels after one year in patients with diabetes remission compared to non-remission, suggesting alanine may be a biomarker for treatment response and diabetes remission.", "population_specificity": "44 obese patients undergoing Roux-en-Y gastric bypass, including 24 with type 2 diabetes at baseline.", "effective_dosage": "Not specified", "study_duration": "Up to one year post-surgery", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:52.460480+00:00"}
{"study_id": 104514, "supplement_id": 863, "safety_score": "40", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine the maximum tolerated dose, pharmacokinetics, and antitumor activity of MEDI-565 in patients with gastrointestinal adenocarcinomas, including its effects on alanine aminotransferase levels.", "results_summary": "The study found dose-limiting toxicities and adverse events, including increased alanine aminotransferase in one patient. No objective tumor responses were observed, though 28% had stable disease.", "population_specificity": "Adults with gastrointestinal adenocarcinomas (72% colorectal cancer).", "effective_dosage": "0.75 \u03bcg to 7.5 mg (with dexamethasone), administered intravenously over 3 hours on days 1-5 every 28 days.", "study_duration": "28-day cycles (exact number of cycles not specified).", "interactions": "Dexamethasone was used in higher-dose cohorts.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:52.636407+00:00"}
{"study_id": 104515, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine if conjugated linoleic acid (CLA) supplementation improves metabolic factors and oxidative stress in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "CLA supplementation, combined with a weight loss diet and vitamin E, significantly improved insulin resistance, lipid profiles, oxidative stress, and liver function markers (e.g., ALT/AST ratio) compared to the control group. The intervention group showed better outcomes in fat mass, muscle mass, total body water, HbA1c, triglycerides, and LDL/HDL ratio.", "population_specificity": "38 obese patients with NAFLD.", "effective_dosage": "Three 1000 mg softgels of CLA daily, alongside a weight loss diet and 400 IU vitamin E.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:53.528189+00:00"}
{"study_id": 104517, "supplement_id": 863, "safety_score": "30", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate MRI as a predictor of IFN-\u03b21\u03b1 treatment efficacy in MS patients, including its association with alanine transferase elevation.", "results_summary": "IFN-\u03b21\u03b1 therapy significantly increased the risk of alanine transferase elevation, indicating potential liver-related safety concerns. The study did not focus on alanine's direct effects but noted its elevation as an adverse outcome.", "population_specificity": "Patients with relapsing-remitting multiple sclerosis (6,037 participants across 10 trials).", "effective_dosage": "Not specified for alanine; IFN-\u03b21\u03b1 dosages varied (low vs. standard dose).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:54.489135+00:00"}
{"study_id": 104518, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to establish blood reference intervals (RIs) for preterm low-birth-weight infants, including alanine aminotransferase (ALT), to aid clinical assessments in neonatal intensive care units (NICUs).", "results_summary": "The study derived blood RIs for 26 items, including ALT, and found that ALT levels increased proportionally with birth weight and gestational age. The results suggest ALT RIs can help in clinical assessments for preterm infants.", "population_specificity": "Preterm low-birth-weight infants admitted to NICUs.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:57.307605+00:00"}
{"study_id": 104520, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to investigate the safety of deferasirox on kidney function in diabetic and nondiabetic \u03b2-thalassemia major patients, focusing on proteinuria as a side effect.", "results_summary": "The study found no significant relationship in spot urine protein/creatinine ratio between diabetic and nondiabetic groups at the end of the study, suggesting deferasirox is safe with only transient proteinuria.", "population_specificity": "Diabetic and nondiabetic \u03b2-thalassemia major patients.", "effective_dosage": "20 to 40 mg/kg/d of deferasirox (Exjade).", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:59.748824+00:00"}
{"study_id": 104522, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety, tolerability, pharmacokinetics, and efficacy of bexarotene (not Alanine) in Japanese patients with cutaneous T-cell lymphomas.", "results_summary": "The abstract does not mention Alanine or its effects; it focuses on bexarotene.", "population_specificity": "Japanese patients with stage IIB-IVB and relapsed/refractory stage IB-IIA cutaneous T-cell lymphomas (CTCL).", "effective_dosage": "300 mg/m\u00b2 once daily (bexarotene, not Alanine).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:00.715350+00:00"}
{"study_id": 104521, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the long-term efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy versus combination therapy with emtricitabine (FTC) in lamivudine-resistant chronic hepatitis B (CHB) patients, not specifically studying alanine.", "results_summary": "The study found that TDF monotherapy was effective and well-tolerated in LAM-R CHB patients over 240 weeks, with similar viral suppression rates between TDF and FTC/TDF groups. Alanine aminotransferase (ALT) normalization rates were comparable between groups, and no TDF resistance was observed.", "population_specificity": "Lamivudine-resistant chronic hepatitis B (CHB) patients", "effective_dosage": "TDF 300mg once daily or FTC 200mg and TDF 300mg once daily", "study_duration": "240 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:01.104235+00:00"}
{"study_id": 104523, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of different rescue therapies, including combinations involving alanine transaminase (ALT) monitoring, for managing clevudine-resistant chronic hepatitis B (CHB).", "results_summary": "The CLV+ADV combination therapy showed the greatest reduction in HBV DNA levels compared to other therapies, with 57.1% achieving undetectable HBV DNA. ALT levels and other markers did not significantly differ between groups.", "population_specificity": "Patients with clevudine-resistant chronic hepatitis B (CHB) and confirmed rtM204I mutation.", "effective_dosage": "Not specified for alanine transaminase (ALT).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:01.791419+00:00"}
{"study_id": 104524, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify and analyze a gene mutation (A317T in THR\u03b2) involving alanine in a Chinese pedigree with thyroid hormone resistance syndrome (THRS).", "results_summary": "The study identified a heterozygous A317T mutation in the THR\u03b2 gene in the proband and his mother, linking it to THRS, while unaffected family members lacked this mutation. The mutation caused a transition from alanine to threonine at position 317 of the THR\u03b2 protein.", "population_specificity": "A Chinese pedigree with thyroid hormone resistance syndrome (THRS), specifically the proband and his mother.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:02.088939+00:00"}
{"study_id": 104525, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of an anthocyanin-rich purple-fleshed sweet potato beverage on serum alanine aminotransferase (ALT) levels in healthy Caucasians with borderline hepatitis.", "results_summary": "The study found that ALT levels in the PSP group were significantly lower on day 43 compared to the placebo group (P=0.037). The PSP beverage did not induce clinically relevant changes in other blood and clinical chemistry parameters.", "population_specificity": "Healthy Caucasians aged 41-69 years with borderline hepatitis.", "effective_dosage": "Three bottles per day (177 mg anthocyanins per 125-ml bottle).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:02.891135+00:00"}
{"study_id": 104526, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore relationships between HCV genotypes, viral load, and biochemical markers, including alanine aminotransferase levels.", "results_summary": "The study found that infection with genotype 1a was associated with significantly higher alanine aminotransferase levels compared to genotype 3a, indicating a potential biochemical impact of HCV genotype on alanine-related markers.", "population_specificity": "1471 HCV-infected patients from six cities in Sindh, Pakistan.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:04.591484+00:00"}
{"study_id": 104519, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine if preconditioning with sevoflurane (not alanine) could protect against ischemia-reperfusion injury in patients undergoing breast reconstruction with deep inferior epigastric perforator flaps.", "results_summary": "The study found that sevoflurane preconditioning led to a significant increase in regional tissue oximetry 4 hours post-surgery and lower creatine phosphokinase levels at the end of surgery, but no long-term differences in other markers.", "population_specificity": "ASA I-II patients undergoing breast reconstruction with deep inferior epigastric perforator flaps.", "effective_dosage": "Not applicable (study focused on anesthesia protocols, not alanine).", "study_duration": "30 minutes before flap removal and throughout surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:06.969664+00:00"}
{"study_id": 104528, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of telbivudine in reducing HBV DNA and normalizing serum alanine aminotransferase levels in chronic hepatitis B patients.", "results_summary": "Telbivudine was shown to rapidly reduce HBV DNA and normalize serum alanine aminotransferase levels, with optimization strategies improving patient responses. Baseline HBV DNA levels were predictive of virological response.", "population_specificity": "Patients with chronic hepatitis B infection.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:08.596257+00:00"}
{"study_id": 104527, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a baseline scoring system to predict the likelihood of sustained virologic response (SVR) in hepatitis C virus genotype 4 (GT4)-infected patients treated with peginterferon alfa-2a and ribavirin.", "results_summary": "The study found that higher baseline scores (0-7) correlated with increased SVR rates (11% to 83%) and lower relapse rates (80% to 7%). SVR rates were consistently higher in Caucasian patients and those with rapid virologic response.", "population_specificity": "Hepatitis C virus genotype 4 (GT4)-infected patients, predominantly from the Middle East and Sub-Saharan Africa.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:08.646440+00:00"}
{"study_id": 104529, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the frequency and factors associated with liver-related specialist care among patients newly diagnosed with HCV, including the role of elevated alanine aminotransferase (ALT) levels.", "results_summary": "Elevated ALT levels were associated with higher odds of receiving specialist care (aOR 1.6 vs. normal ALT) and prompt care within 90 days (aOR 1.3-2.3 vs. normal). Patients referred to specialists were more likely to receive HCV treatment (aOR 3.5).", "population_specificity": "Patients newly diagnosed with HCV in four US healthcare organizations (2006-2011).", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:10.614537+00:00"}
{"study_id": 104531, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of cetuximab combined with XELOX (capecitabine and oxaliplatin) in patients with previously untreated KRAS wild-type metastatic colorectal cancer (mCRC).", "results_summary": "The combination therapy showed a confirmed overall response rate of 50%, within the previously reported range, and demonstrated an acceptable safety profile with manageable adverse events. The study concluded that further investigation of this combination is warranted due to its convenience and potential cost-saving benefits.", "population_specificity": "Patients with previously untreated KRAS wild-type metastatic colorectal cancer (mCRC).", "effective_dosage": "Median dose intensity of 218 mg/m\u00b2 (specific frequency not detailed in abstract).", "study_duration": "Median treatment cycle number was 8 (specific duration not detailed in abstract).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:11.461364+00:00"}
{"study_id": 104530, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy of drug treatment alone versus drug treatment combined with percutaneous needle aspiration in patients with amebic liver abscess (ALA), particularly focusing on abscess size (small vs. large).", "results_summary": "The study found that combining needle aspiration with metronidazole significantly improved clinical outcomes (e.g., reduced body temperature, liver tenderness, serum ALT levels) and accelerated abscess cavity reduction, especially in large abscesses (5\u201310 cm). Aspiration was also reported as safe with no major complications.", "population_specificity": "Patients with amebic liver abscess (ALA), categorized by abscess size (small: up to 5 cm; large: 5\u201310 cm).", "effective_dosage": "Not specified (metronidazole dosage not detailed in abstract).", "study_duration": "Outcomes assessed at days 8, 15, 1 month, and 3 months post-intervention.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:12.062546+00:00"}
{"study_id": 104532, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) for preventing mother-to-child transmission of HBV, not specifically evaluating Alanine.", "results_summary": "The abstract does not report results related to Alanine, as the study focuses on TDF for HBV transmission prevention.", "population_specificity": "Pregnant women in Thailand with chronic HBV infection, HBsAg and HBeAg positive, ALT <30 IU/L, and no prior antiviral treatment.", "effective_dosage": "Not applicable (study focused on TDF, not Alanine).", "study_duration": "From 28 weeks' gestation through 2 months postpartum.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:12.110439+00:00"}
{"study_id": 104533, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the efficacy and safety of nilotinib in Turkish patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), not specifically Alanine.", "results_summary": "The study found that 66.1% of patients achieved major molecular response (MMR) and 22.3% achieved deep molecular response (MR4.5) by 12 months. Adverse events included elevations in bilirubin, alanine aminotransferase, and triglycerides, but most were grade 1/2.", "population_specificity": "Turkish patients with newly diagnosed CML-CP.", "effective_dosage": "300 mg twice daily (nilotinib, not Alanine).", "study_duration": "12 months (first phase of a 24-month study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:13.308845+00:00"}
{"study_id": 104534, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers compared the outcomes of conventional transarterial chemoembolization versus drug-eluting bead chemoembolization for treating neuroendocrine tumor liver metastases, not specifically evaluating Alanine.", "results_summary": "The study found that conventional chemoembolization had better symptomatic response, while DEB chemoembolization resulted in lower liver function test elevations and less postembolization syndrome. No differences were observed in biochemical or radiologic responses.", "population_specificity": "Patients with neuroendocrine tumor liver metastases (93% bilobar distribution).", "effective_dosage": "Not mentioned (study focused on chemoembolization techniques, not Alanine).", "study_duration": "Evaluated at 1-month follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:15.560330+00:00"}
{"study_id": 104536, "supplement_id": 863, "safety_score": "65", "efficacy_score": 80, "quality_score": 85, "study_goal": "The study aimed to evaluate the efficacy and safety of teriflunomide in reducing relapse frequency and disability progression in patients with relapsing multiple sclerosis (RMS), with incidental findings on alanine aminotransferase levels.", "results_summary": "The study found that teriflunomide significantly reduced annualized relapse rates and disability progression in RMS patients, but elevated alanine aminotransferase levels were more common with teriflunomide compared to placebo. Serious adverse events were similar across groups.", "population_specificity": "Patients with relapsing multiple sclerosis (RMS).", "effective_dosage": "Teriflunomide 7mg and 14mg (specific frequency not mentioned).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.928410+00:00"}
{"study_id": 104535, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to examine the effect of antiviral therapy on hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients based on alanine aminotransferase (ALT) levels.", "results_summary": "Antiviral treatment significantly reduced HCC risk, with a hazard ratio of 0.24, and was effective even in patients with ALT <2\u00d7ULN. The number-needed-to-treat (NNT) to prevent one HCC case at 10 years was low (14-15) for patients with HBV DNA \u22652000 IU/mL, regardless of ALT levels.", "population_specificity": "Treatment-na\u00efve, noncirrhotic CHB patients aged \u226540 years from the United States and Taiwanese REVEAL-HBV cohort (n=3665).", "effective_dosage": "Not specified", "study_duration": "10 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.963412+00:00"}
{"study_id": 104539, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review therapeutic options targeting the Akt pathway to reduce hepatic ischemia/reperfusion (I/R) injury, including the role of alanine aminotransferase levels as a marker of hepatocyte damage.", "results_summary": "The study found that Akt activation through various therapies (preconditioning, postconditioning, pharmacological intervention, and miRNA/gene therapy) reduced hepatocyte damage, as evidenced by serum alanine aminotransferase levels and liver histology. These therapies showed predictable protective effects in mitigating hepatic I/R injury.", "population_specificity": "Hepatic transplant patients or those at risk of hepatic I/R injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:20.343921+00:00"}
{"study_id": 104537, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the efficacy and safety of cobimetinib combined with vemurafenib in treating advanced BRAF(V600)-mutant melanoma, not specifically Alanine.", "results_summary": "The study found that cobimetinib plus vemurafenib improved progression-free and overall survival compared to vemurafenib alone, with manageable safety profiles. Alanine transaminase increase was noted as a common adverse event in the combination group.", "population_specificity": "Adult patients (aged \u226518 years) with BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma.", "effective_dosage": "Not applicable (study focused on cobimetinib and vemurafenib, not Alanine).", "study_duration": "Median follow-up of 14.2 months (IQR 8.5-17.3).", "interactions": "None mentioned (related to Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:20.582131+00:00"}
{"study_id": 104540, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to quantify the hepatic safety of pazopanib and other anti-VEGF therapies, including monitoring alanine aminotransferase (ALT) levels, in renal cell carcinoma (RCC) patients.", "results_summary": "The study found few cases of severe liver injury (ALT \u22658\u00d7 upper limit of normal) across anti-VEGF therapies, with pazopanib showing the highest incidence rates. No Hy's law cases were identified for pazopanib or bevacizumab, and only one adjudicated drug-induced liver injury (DILI) case was observed (sunitinib).", "population_specificity": "Renal cell carcinoma (RCC) patients in the US (VA and Altos databases) and The Netherlands (PHARMO Database Network).", "effective_dosage": "Not specified", "study_duration": "Up to 4 years of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:21.431785+00:00"}
{"study_id": 104538, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy of low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai patients with HIV, not specifically focusing on Alanine.", "results_summary": "The study found that low-dose atazanavir was non-inferior to standard-dose in maintaining viral suppression, with fewer discontinuations and lower bilirubin toxicity in the low-dose group. Alanine aminotransferase levels were an inclusion criterion but not a primary focus of the results.", "population_specificity": "Thai patients with HIV, aged 18 or older, virologically suppressed on protease-inhibitor-based ART.", "effective_dosage": "Not applicable (study focused on atazanavir, not Alanine).", "study_duration": "48 weeks.", "interactions": "None mentioned (related to Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:21.629664+00:00"}
{"study_id": 104541, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of combining all-trans retinoic acid (ATRA) with ursodeoxycholic acid (UDCA) on markers like alanine aminotransferase (ALT) in patients with primary sclerosing cholangitis (PSC).", "results_summary": "The combination significantly reduced ALT levels and the bile acid intermediate C4, though it did not significantly affect the primary endpoint (ALP). After washout, ALT levels returned to baseline.", "population_specificity": "Patients with PSC who had an incomplete response to UDCA monotherapy.", "effective_dosage": "ATRA (45 mg/m\u00b2/day, divided twice daily) combined with moderate-dose UDCA.", "study_duration": "12 weeks of combination therapy followed by a 12-week washout.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:23.019259+00:00"}
{"study_id": 104542, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the long-term effectiveness and durability of entecavir (ETV) treatment in chronic hepatitis B patients, including predictors of virologic response and relapse rates after treatment cessation.", "results_summary": "The study found that ETV monotherapy achieved high virologic response rates (85.8% at year 1, 97.6% at year 3), but relapse rates were high (91.3% within 2 years after treatment cessation). ETV showed limited efficacy in preventing hepatocellular carcinoma in cirrhosis patients.", "population_specificity": "2240 chronic hepatitis B patients, including 804 treatment-naive patients receiving ETV monotherapy.", "effective_dosage": "Not specified", "study_duration": "Mean treatment duration was 712\u00b1493 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.434832+00:00"}
{"study_id": 104546, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate how alcoholic hepatitis affects the urea synthesis capacity, measured via functional hepatic nitrogen clearance (FHNC) during alanine infusion, and its relation to disease severity.", "results_summary": "The study found that alcoholic hepatitis significantly decreased urea synthesis capacity (FHNC), with the most severe cases showing the largest reduction. This decrease correlated with increased clinical disease severity, indicating metabolic failure in alcoholic hepatitis patients.", "population_specificity": "20 patients with alcoholic hepatitis and 7 healthy controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:27.910265+00:00"}
{"study_id": 104543, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether elevated ALP levels are associated with hemorrhagic transformation (HT) risk, particularly symptomatic HT, in ischemic stroke patients with atrial fibrillation and/or rheumatic heart disease.", "results_summary": "ALP levels were not associated with overall HT risk but were significantly linked to an increased likelihood of symptomatic HT in the highest tertile (8.96 times higher risk). No association was found for non-symptomatic HT subtypes (HI, PH).", "population_specificity": "Ischemic stroke patients with atrial fibrillation and/or rheumatic heart disease (n=130, mean age 63 years).", "effective_dosage": "Not specified (ALP levels measured within 48 hours post-admission, divided into tertiles).", "study_duration": "Not specified (single measurement within 48 hours).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:27.943094+00:00"}
{"study_id": 104544, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine clinical and laboratory parameters used for discharging patients with Crimean-Congo Hemorrhagic Fever (CCHF), including the role of Alanine aminotransferase (ALT) levels.", "results_summary": "ALT levels were either normal or not higher than 10-fold and showed a tendency to decrease in 99.6% of patients, but ALT and AST levels were not prioritized as discharge criteria. No complications, relapses, or secondary transmissions were reported post-discharge.", "population_specificity": "Laboratory-confirmed CCHF patients (n=260) from 9 reference centers, with a mean age of 51.3 years and 60.8% male.", "effective_dosage": "Not available", "study_duration": "Mean hospital stay was 7 \u00b1 2.6 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:28.002044+00:00"}
{"study_id": 104545, "supplement_id": 863, "safety_score": "60", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy and safety of basal insulin peglispro (BIL) versus insulin glargine (GL) in managing HbA1c levels in adults with type 1 diabetes.", "results_summary": "BIL showed superior HbA1c reduction, less nocturnal hypoglycemia, and weight loss compared to GL, but was associated with increased total and severe hypoglycemia, elevated alanine aminotransferase, and more injection site reactions.", "population_specificity": "Adults with type 1 diabetes (n=455).", "effective_dosage": "Not specified (bedtime administration).", "study_duration": "26 weeks (primary endpoint), total study duration 78 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:28.848212+00:00"}
{"study_id": 104547, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate factors affecting response rates and adverse events associated with triple therapy (PEG-IFN\u03b1/RBV/Boc or Tel) compared to dual therapy (PEG-IFN\u03b1/RBV) in genotype 1 HCV patients, particularly focusing on pretreatment alanine aminotransferase (ALT) levels.", "results_summary": "Triple therapy increased sustained virological response (SVR) rates, especially in treatment-experienced patients and those with elevated pretreatment ALT levels, but also led to higher rates of serious adverse events and treatment discontinuation.", "population_specificity": "Patients with genotype 1 HCV infection, particularly those previously treated with PEG-IFN\u03b1/RBV and with increased pretreatment ALT levels.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:29.685402+00:00"}
{"study_id": 104548, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the long-term outcomes of chronic hepatitis B patients treated with lamivudine, focusing on HBsAg clearance and clinical improvements.", "results_summary": "Long-term lamivudine therapy led to HBsAg loss in a substantial proportion of patients, particularly HBeAg-negative individuals, with no relapse observed post-treatment. However, serious outcomes persisted in patients with pre-existing cirrhosis who did not clear HBsAg.", "population_specificity": "42 patients with chronic hepatitis B (22 HBeAg-positive, 20 HBeAg-negative).", "effective_dosage": "Not specified", "study_duration": "3.2-19.5 years (median = 16.1 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:30.407407+00:00"}
{"study_id": 104549, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the relationship between ultrasonographic detection of intestinal gas and liver steatosis, including the role of alanine transaminase (ALT) as a biochemical marker.", "results_summary": "The study found a significant correlation between excessive intestinal gas and liver steatosis, with elevated ALT levels further reinforcing this association. Intestinal gas and BMI were identified as independent predictors of liver steatosis.", "population_specificity": "204 consecutive patients (99 male; mean age 53.0 \u00b1 15.6 years) undergoing ultrasonography for abdominal complaints or follow-up of benign lesions.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:32.167102+00:00"}
{"study_id": 104550, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety of an aqueous cyanophyta extract (ACE) containing phycocyanin, focusing on anticoagulant activity and platelet activation, and its effects on liver function markers like alanine transaminase (ALT).", "results_summary": "The study found no adverse effects on anticoagulant activity or platelet activation markers. ACE consumption significantly reduced AST levels and showed a trend toward reduced ALT levels, suggesting improved liver function. It also provided significant relief from chronic pain.", "population_specificity": "24 men and women in a randomized, double-blind, placebo-controlled study.", "effective_dosage": "2.3 g/day of ACE (equivalent to ~1 g phycocyanin per day).", "study_duration": "2 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:34.228731+00:00"}
{"study_id": 104551, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of weight loss (via diet and exercise) on biochemical parameters, including Alanine Aminotransferase (ALT), in obese patients with non-alcoholic steatohepatitis (NASH).", "results_summary": "The study found that weight loss significantly decreased ALT levels in the intervention group (diet and exercise), indicating improved liver function, while no significant changes were observed in the control group.", "population_specificity": "Obese patients (BMI 30-35 kg/m\u00b2) aged 35-50 years with NASH.", "effective_dosage": "Not specified (intervention involved moderate aerobic exercise and diet regimen).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:36.362376+00:00"}
{"study_id": 104554, "supplement_id": 863, "safety_score": "65", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy and safety of basal insulin peglispro versus insulin glargine in insulin-na\u00efve adults with type 2 diabetes, focusing on glycemic control and adverse effects.", "results_summary": "Peglispro was non-inferior to glargine in HbA1c reduction, showed lower nocturnal hypoglycemia rates, and achieved more patients reaching HbA1c targets, but it resulted in higher triglyceride and aminotransferase levels and more injection site reactions. Liver fat content remained unchanged with peglispro but decreased with glargine.", "population_specificity": "Insulin-na\u00efve adults with type 2 diabetes.", "effective_dosage": "Not specified in the abstract.", "study_duration": "52 or 78 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:37.367042+00:00"}
{"study_id": 104553, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of tabalumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma (RRMM).", "results_summary": "The study found that combined treatment with tabalumab, bortezomib, and dexamethasone was well tolerated, with common adverse events including thrombocytopenia, lymphopenia, and increased alanine aminotransferase. The overall response rate was 56.3%, suggesting efficacy.", "population_specificity": "Japanese patients with relapsed or refractory multiple myeloma (RRMM)", "effective_dosage": "Tabalumab 100 mg or 300 mg intravenously, dexamethasone 20 mg/day orally, and bortezomib 1.3 mg/m\u00b2 intravenously or subcutaneously", "study_duration": "Not specified in the abstract", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:37.804895+00:00"}
{"study_id": 104552, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the effects of anagliptin (a DPP-4 inhibitor) and glimepiride on arterial stiffness, measured by CAVI, in patients with type 2 diabetes, and to assess whether anagliptin's benefits were independent of glucose-lowering effects.", "results_summary": "Anagliptin significantly reduced arterial stiffness (CAVI), LDL cholesterol, malondialdehyde-modified LDL, remnant-like particle cholesterol, alanine transaminase (ALT), \u03b3-glutamyl transferase, and visceral fat volume, unlike glimepiride. Changes in RLP cholesterol and ALT were independently correlated with improvements in arterial stiffness.", "population_specificity": "50 outpatients (33 males, 17 females; mean age 72.5\u00b19.5 years) with type 2 diabetes.", "effective_dosage": "Not specified in the abstract.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:37.820683+00:00"}
{"study_id": 104555, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were attempting to diagnose and treat a rare case of primary MALT lymphoma mimicking hilar cholangiocarcinoma in an elderly female patient.", "results_summary": "The study found that the patient's obstructive jaundice and abdominal pain were caused by MALT lymphoma, not cholangiocarcinoma, and that complete resection cured the condition with no recurrence after one year.", "population_specificity": "An 86-year-old female with obstructive jaundice and abdominal pain.", "effective_dosage": "Not applicable (surgical intervention).", "study_duration": "Postoperative follow-up of 1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:38.448885+00:00"}
{"study_id": 104557, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not investigate Alanine; it evaluated the efficacy and safety of pazopanib and sunitinib in metastatic renal cell carcinoma patients with poor-risk features.", "results_summary": "The study did not report any findings related to Alanine.", "population_specificity": "Metastatic renal cell carcinoma patients with poor-risk features.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:38.753794+00:00"}
{"study_id": 104556, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were evaluating the safety and efficacy of crizotinib for treating ROS1-positive metastatic non-small cell lung cancer, not specifically studying alanine.", "results_summary": "The study found that crizotinib demonstrated a clinically meaningful objective response rate in ROS1-positive mNSCLC patients, with common adverse reactions including elevated alanine transaminase levels.", "population_specificity": "Patients with ROS1-positive metastatic non-small cell lung cancer (age range: 25-77 years).", "effective_dosage": "250 mg twice daily.", "study_duration": "Median duration of exposure was 34.4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:39.522308+00:00"}
{"study_id": 104558, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effectiveness of \u03c9-3 PUFAs-based lipid emulsions (including Alanine as part of the metabolic response) in controlling inflammation and protecting liver function post-hepatectomy.", "results_summary": "The study found that \u03c9-3 PUFAs-based lipid emulsions significantly reduced inflammation markers (WBC, ALT, AST, TBil) and complications while improving liver function (Pre-Alb) and shortening hospital stays post-surgery.", "population_specificity": "Patients after liver resection (n=119).", "effective_dosage": "Omegaven\u00ae 10% 100 mL/day.", "study_duration": "5 days postoperatively.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:42.522312+00:00"}
{"study_id": 104559, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the relationship between baseline alanine aminotransferase (ALT) levels within the normal range and cardiovascular risk, as well as whether ALT levels modified the efficacy of statin therapy.", "results_summary": "The study found that higher baseline ALT levels within the normal range were inversely associated with future cardiovascular risk, with the lowest tertile of ALT showing the highest event rates. Statin therapy efficacy was not influenced by baseline ALT levels.", "population_specificity": "17,515 men and women free of cardiovascular disease, with baseline ALT levels below 40 IU/l.", "effective_dosage": "Rosuvastatin 20 mg/day (intervention group).", "study_duration": "Followed prospectively for first-ever cardiovascular events (duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:45.175838+00:00"}
{"study_id": 104560, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the characteristics of exercise programs that optimally improve liver function in overweight adults or those with fatty liver disease.", "results_summary": "The study found that exercise training with a total workload exceeding 10,000 kcal significantly reduced intrahepatic fat and free fatty acids while improving cardiorespiratory fitness.", "population_specificity": "Adults who were overweight, obese, or had fatty liver disease (non-alcoholic fatty liver disease or non-alcoholic steatohepatitis).", "effective_dosage": "Not specified (exercise workload >10,000 kcal total).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:45.214802+00:00"}
{"study_id": 104561, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review peptide scanning techniques, including alanine scanning, and their impact on optimizing peptide pharmacological properties for drug discovery.", "results_summary": "The abstract highlights that peptide scanning techniques, such as alanine scanning, provide systematic insights into peptide structure-activity relationships and pharmacological properties, offering new perspectives for peptide drug development.", "population_specificity": "Not specified (review article)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:45.708497+00:00"}
{"study_id": 104562, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of tenofovir disoproxil fumarate (TDF) in reducing mother-to-child transmission of HBV, including monitoring alanine aminotransferase (ALT) elevations as a safety measure.", "results_summary": "TDF significantly reduced HBV DNA levels in mothers and lowered mother-to-child transmission rates. However, ALT elevations occurred more frequently in the TDF group after discontinuation, indicating potential liver-related side effects.", "population_specificity": "HBeAg-positive pregnant women with HBV DNA levels >200,000 IU/mL.", "effective_dosage": "300 mg per day orally.", "study_duration": "From 30-32 weeks of gestation until postpartum week 4.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:46.277353+00:00"}
{"study_id": 104564, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the feasibility and potential complications of rabbit anti-thymocyte globulin (rATG) for treating steroid-resistant acute rejection (SRAR) in liver transplant recipients, not specifically Alanine.", "results_summary": "The study found that rATG effectively treated SRAR, with significant reductions in AST, ALT, and bilirubin levels, but noted complications like HCV reactivation and CMV infection.", "population_specificity": "Liver transplant recipients with steroid-resistant acute rejection (n=11).", "effective_dosage": "2.5 mg/kg rATG for 6 to 10 days.", "study_duration": "6 to 10 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:47.338612+00:00"}
{"study_id": 104565, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the effect of HAART on liver function, specifically alanine aminotransferase (ALT) levels, in under-five children with HIV.", "results_summary": "The study found that ALT levels were initially elevated in HIV-infected children on HAART, suggesting hepatotoxicity, but significantly decreased after 3 and 6 months of monitoring, indicating resolved hepatotoxicity.", "population_specificity": "Under-five children in Southern Nigeria, including HIV-infected children on HAART and seronegative controls.", "effective_dosage": "Not specified for alanine; HAART and other medications (nevirapine, co-trimoxazole) were administered as per standard protocols.", "study_duration": "6 months of monitoring for the HAART group.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:47.928130+00:00"}
{"study_id": 104563, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize the safety profile of ambrisentan, particularly focusing on the incidence of aminotransferase elevations (including alanine aminotransferase) in patients with pulmonary arterial hypertension (PAH).", "results_summary": "The study found a low incidence of alanine aminotransferase elevations (>3\u00d7 ULN) at 0.02 per patient-year, with no new safety signals identified. Adverse events of special interest, such as edema/fluid retention and anemia, were reported but were consistent with known profiles.", "population_specificity": "Patients with PAH (Functional Class II and III), including those with PAH associated with connective tissue disease (PAH-CTD) and PAH-specific-therapy-naive individuals.", "effective_dosage": "Not specified", "study_duration": "Data collected between 30 June 2008 and 13 May 2011 (approximately 2.9 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:48.064026+00:00"}
{"study_id": 104566, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether supplementation with high-concentration glucose and amino acids (including alanine) could improve energy and protein status in non-diabetic hemodialysis patients.", "results_summary": "The glucose group showed significantly higher post-treatment concentrations of alanine and other amino acids compared to baseline. The amino acid group had significantly higher albumin and prealbumin levels compared to other groups, indicating improved protein status.", "population_specificity": "Non-diabetic patients receiving long-term maintenance hemodialysis for chronic kidney disease.", "effective_dosage": "8.5% amino acids solution (specific dosage not detailed).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:51.381921+00:00"}
{"study_id": 104567, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to investigate the effects of curcumin on hepatic fat content and biochemical/anthropometric features in patients with NAFLD, not Alanine.", "results_summary": "The study found curcumin significantly reduced liver fat content, improved lipid and glycemic profiles, and was well-tolerated, but it did not assess Alanine.", "population_specificity": "Patients with ultrasonographic evidence of NAFLD.", "effective_dosage": "Not applicable (study used curcumin, not Alanine).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:52.220746+00:00"}
{"study_id": 104568, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy and safety of basal insulin peglispro (BIL) with insulin glargine (GL) in patients with type 1 diabetes, focusing on glycemic control and adverse effects.", "results_summary": "BIL resulted in lower HbA1c levels, more patients achieving HbA1c <7%, and reduced nocturnal hypoglycemia compared to GL, but it also increased total hypoglycemia, injection site reactions, and elevated triglyceride and ALT levels.", "population_specificity": "Adults with type 1 diabetes (n=1114).", "effective_dosage": "Not specified (administered at bedtime with preprandial insulin lispro).", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.984007+00:00"}
{"study_id": 104569, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the non-inferiority and potential superiority of S-1 versus gemcitabine as adjuvant chemotherapy for resected pancreatic cancer, not specifically focused on Alanine.", "results_summary": "The study found that S-1 was non-inferior and superior to gemcitabine in overall survival for resected pancreatic cancer, with a 5-year survival rate of 44.1% for S-1 versus 24.4% for gemcitabine. Alanine aminotransferase elevation was more frequent in the gemcitabine group, but the study did not focus on Alanine's effects.", "population_specificity": "Japanese patients with resected pancreatic cancer (stage I-III).", "effective_dosage": "Not applicable (study focused on S-1 and gemcitabine, not Alanine).", "study_duration": "Up to six cycles (gemcitabine) or four cycles (S-1).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:55.754050+00:00"}
{"study_id": 104573, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the role of BMI and gender differences in NAFLD and identify risk factors, including alanine transaminase (ALT), associated with the disease.", "results_summary": "The study found that ALT was a steady risk factor for NAFLD in both males and females, with high performance for NAFLD discrimination. TG, ALT, and uric acid were common risk factors in both genders.", "population_specificity": "8,817 general adult subjects divided into underweight, normal, overweight, and obese groups by gender.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:55.824089+00:00"}
{"study_id": 104570, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the combined effects of exercise capacity and coronary artery calcium score (CACS) on all-cause mortality in an asymptomatic population, adjusting for factors including alanine transaminase.", "results_summary": "The study found that higher exercise capacity (\u226510 METs) reduced the adverse effect of high CACS on all-cause mortality, with alanine transaminase included as a covariate in the analysis.", "population_specificity": "Asymptomatic adults (mean age 53.7 \u00b1 7.7 years, 81.5% male) undergoing health screening.", "effective_dosage": "Not available", "study_duration": "Median follow-up of 5.5 years (IQR 3.6-7.5)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:56.407438+00:00"}
{"study_id": 104572, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the current treatment landscape for chronic HBV infection in children, including the role of alanine aminotransferase levels as a marker for treatment eligibility.", "results_summary": "The study found that current treatments for HBV in children are only partially effective, with limited serological responses. Alanine aminotransferase levels above 1.5-2 times the upper limit of normal for over 6 months were identified as a criterion for treatment eligibility in non-immunotolerant cases.", "population_specificity": "Children with chronic HBV infection, particularly those with elevated alanine aminotransferase levels.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:56.509595+00:00"}
{"study_id": 104571, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the prevalence and predictors of chronic liver disease (CLD) in HIV-monoinfected individuals with persistently elevated alanine aminotransferase (ALT) levels, focusing on metabolic syndrome, alcohol use, and antiretroviral therapy as potential risk factors.", "results_summary": "The study found that 27% of HIV-monoinfected individuals had persistently elevated ALT levels, with 66.2% of those investigated showing some degree of non-viral CLD. Risk factors included alcohol use, hepatotoxic antiretrovirals, and metabolic syndrome components, with serum triglyceride levels being the only independent predictor of CLD.", "population_specificity": "HIV-positive individuals with negative HBV/HCV serology and at least two elevated ALT levels six months apart.", "effective_dosage": "Not specified", "study_duration": "Retrospective cohort study spanning 2005-2012", "interactions": "Hepatotoxic antiretrovirals were noted as a risk factor for CLD.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:58.756935+00:00"}
{"study_id": 104575, "supplement_id": 863, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of combining Chinese herbs with interferon and ribavirin for treating chronic hepatitis C (CHC), including the impact on alanine transaminase (ALT) levels.", "results_summary": "The combination therapy significantly improved ALT levels and viral response while reducing adverse events like leukocyte count decrease, abnormal thyroid function, psychosis, and anemia compared to standard therapy.", "population_specificity": "Patients with chronic hepatitis C (CHC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:00.643208+00:00"}
{"study_id": 104574, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety, tolerability, and antitumour activity of pembrolizumab in patients with PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck, not specifically Alanine.", "results_summary": "The study found that pembrolizumab was well tolerated, with some patients experiencing grade 3-4 drug-related adverse events, including increases in alanine aminotransferase. The overall response rate was 18% in all patients, with higher rates in HPV-positive patients (25%) compared to HPV-negative patients (14%).", "population_specificity": "Patients aged 18 or older with recurrent or metastatic squamous cell carcinoma of the head and neck and PD-L1 expression.", "effective_dosage": "Pembrolizumab 10 mg/kg intravenously every 2 weeks.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:00.896695+00:00"}
{"study_id": 104577, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop comprehensive clinical practice guidelines for obesity management, not specifically focused on Alanine.", "results_summary": "The abstract does not report specific findings related to Alanine, as the focus was on obesity management guidelines.", "population_specificity": "Patients with obesity (general population, not specific to Alanine).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:02.142270+00:00"}
{"study_id": 104576, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the treatment outcomes of daclatasvir (DCV) and asunaprevir (ASV) therapy for chronic hepatitis C (HCV) in patients with liver cirrhosis, focusing on resistance-associated variants (RAVs) in the NS3/NS5A regions.", "results_summary": "The study found that the SVR12 rate was significantly higher in patients with NS5A 93Y (wild) compared to those with NS5A 93H mutations. Virological failure was more common in patients with prior simeprevir (SMV) therapy failure and pre-existing NS3/4A 168 substitutions.", "population_specificity": "Patients in Japan with HCV-1b, including those with liver cirrhosis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:03.606536+00:00"}
{"study_id": 104579, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine the effect of intragastric balloon therapy on liver enzymes, particularly alanine aminotransferase (ALT), and markers of nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that intragastric balloon therapy significantly reduced ALT levels and improved markers of NAFLD, including hepatic steatosis and histological NAFLD activity scores, over a 6-month period.", "population_specificity": "Overweight or obese adult patients undergoing intragastric balloon placement.", "effective_dosage": "Not specified (intervention was intragastric balloon therapy, not direct alanine supplementation).", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:04.965875+00:00"}
{"study_id": 104580, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers compared clinical outcomes between hepatic dysfunction phase I clinical trials (HDCT) and phase I clinical trials (P1CT) to assess patterns of drug-induced liver injury (DILI), including effects on alanine aminotransferase (ALT).", "results_summary": "The study found worsening of ALT in subjects on P1CT, with differing patterns of DILI between HDCT and P1CT. Cholestatic peak patterns were more frequent in HDCT, while Hy's law criteria were met only in P1CT subjects.", "population_specificity": "Subjects with hepatic dysfunction (HDCT) and standard phase I clinical trial participants (P1CT).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:05.135876+00:00"}
{"study_id": 104578, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if a glucagon-like peptide-1 agonist-based regimen (GLIPULIN) could reduce glycemic variability and cardiometabolic risk markers, including alanine aminotransferase, while maintaining similar A1C levels in people with insulin-requiring type 2 diabetes and high cardiovascular risk.", "results_summary": "GLIPULIN reduced glycemic variability, weight, and some cardiometabolic risk markers (including alanine aminotransferase) while maintaining equivalent A1C levels compared to basal-bolus insulin. No differences in hypoglycemic events or arrhythmias were observed between the groups.", "population_specificity": "People with insulin-requiring type 2 diabetes and high cardiovascular risk (n=102).", "effective_dosage": "Not specified for alanine; exenatide was dosed before the two largest meals.", "study_duration": "26 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:05.333712+00:00"}
{"study_id": 104583, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the long-term efficacy and safety of sitagliptin treatment in elderly patients with type 2 diabetes mellitus, not specifically Alanine.", "results_summary": "The study found that sitagliptin significantly reduced HbA1c levels over 24 months and allowed for a reduction in sulfonylurea dosage, but did not specifically assess Alanine's effects.", "population_specificity": "Japanese type 2 diabetes patients over 65 years of age.", "effective_dosage": "Not applicable (study focused on sitagliptin, not Alanine).", "study_duration": "24 months.", "interactions": "None mentioned (related to Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:08.793583+00:00"}
{"study_id": 104582, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to examine the impact of body mass index on the efficacy and safety of ipragliflozin, including its effects on alanine aminotransferase levels.", "results_summary": "The study found that ipragliflozin significantly reduced hemoglobin A1c, fasting plasma glucose, and bodyweight across all BMI categories, with a weak correlation between hemoglobin A1c and bodyweight changes. Alanine aminotransferase levels showed a greater placebo-subtracted difference in patients with higher BMI, but adverse event incidences were similar between ipragliflozin and placebo groups.", "population_specificity": "Japanese patients with varying body mass index categories.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:09.323269+00:00"}
{"study_id": 104581, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of Vitamin E versus Ursodeoxycholic acid (UDCA) in nondiabetic nonalcoholic fatty liver disease (NAFLD) patients, focusing on normalization of alanine aminotransferase (ALT) levels.", "results_summary": "The study found no significant difference between Vitamin E and UDCA in achieving ALT normalization (14% vs. 19%), reduction in ALT levels (56% vs. 63%), symptomatic improvement (78% vs. 67%), or reduction in NAFLD Fibrosis score (44% vs. 47%). Both treatments were similarly tolerated.", "population_specificity": "Nondiabetic, noncirrhotic Indian NAFLD patients with raised ALT levels (>40 IU/L).", "effective_dosage": "Vitamin E 400 mg twice daily; UDCA 300 mg twice daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:09.391653+00:00"}
{"study_id": 104584, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether vitamin D supplementation in cirrhotic patients with low 25(OH)D levels could increase serum 25(OH)D concentrations and improve liver function markers, including alanine aminotransferase (ALT).", "results_summary": "The study found that vitamin D supplementation significantly increased 25(OH)D serum concentrations but had no significant effect on secondary outcomes, including ALT levels.", "population_specificity": "36 patients with cirrhosis and 25(OH)D concentrations below 30 ng/mL.", "effective_dosage": "2800 International Units of vitamin D3 per day as oily drops.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:10.348676+00:00"}
{"study_id": 104585, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to assess the correlation between liver function markers (AST and ALT) and disease severity in dengue virus-infected patients, with a focus on the role of IL-2.", "results_summary": "The study found significantly elevated ALT (alanine aminotransferase) levels in dengue-infected patients, correlating with disease severity and IL-2 levels. No direct assessment of alanine supplementation or its effects was conducted.", "population_specificity": "Dengue fever (DF) and dengue hemorrhagic fever (DHF) patients, healthy adults, and typhoid patients.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.648556+00:00"}
{"study_id": 104587, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the effectiveness of exercise-based lifestyle interventions on reducing alanine aminotransferase levels in patients with NAFLD and metabolic disorders.", "results_summary": "The study found that physical activity significantly reduced alanine aminotransferase levels (weighted mean difference: -3.30 IU/L) in patients with NAFLD, indicating improved liver health. The effect was more pronounced in individuals with higher baseline body mass index.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD) and underlying metabolic disorders such as obesity, type 2 diabetes, or metabolic syndrome.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:13.372007+00:00"}
{"study_id": 104588, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the role of perioperative prostaglandin E1 (PGE1) infusion in reducing early allograft dysfunction and improving postoperative outcomes in living donor liver transplantation (LDLT).", "results_summary": "PGE1 infusion reduced the incidence of acute kidney injury (AKI) and lowered postoperative alanine aminotransferase levels, but did not significantly affect early allograft dysfunction or other liver function parameters. No differences were observed in hepatic artery thrombosis, postoperative bleeding, mortality, or hospital stay.", "population_specificity": "Patients undergoing living donor liver transplantation (LDLT).", "effective_dosage": "0.25 \u03bcg/kg/hour, starting 1 hour after portal venous reperfusion.", "study_duration": "96 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:15.664223+00:00"}
{"study_id": 104586, "supplement_id": 863, "safety_score": "85", "efficacy_score": 70, "quality_score": 90, "study_goal": "The researchers aimed to assess whether increasing the dose of rifampicin (RMP) resulted in increased hepatic adverse events, specifically focusing on serum alanine transferase (ALT) levels.", "results_summary": "The study found a non-significant trend of increased grade 3 ALT levels with higher RMP doses (1% in R10, 2% in R15, 4% in R20), but no grade 4 increases. One case of jaundice occurred in the R15 group. Culture negativity at 8 weeks showed a non-significant improvement with higher RMP doses.", "population_specificity": "300 HIV-negative patients with newly diagnosed microscopy-positive pulmonary tuberculosis.", "effective_dosage": "RMP doses of 10 mg/kg (control), 15 mg/kg (R15), and 20 mg/kg (R20) daily.", "study_duration": "8 weeks of intensive phase (with EMB, INH, RMP, pyrazinamide), followed by 18 weeks of continuation phase (INH and RMP).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:17.052714+00:00"}
{"study_id": 104589, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effect of acute mangosteen supplementation on physical fatigue during exercise, including its impact on alanine aminotransferase as a biochemical marker.", "results_summary": "The study found that acute mangosteen supplementation had no significant impact on alleviating physical fatigue during exercise, except for a positive effect on mood states (POMS). All examined parameters, including alanine aminotransferase, were significantly altered by exercise but showed no differences between the mangosteen and placebo treatments.", "population_specificity": "12 healthy adults", "effective_dosage": "250 mL of mangosteen-based juice (containing 305 mg of \u03b1-mangostin and 278 mg of hydroxycitric acid), administered once 1 hour before exercise", "study_duration": "Acute (single dose)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.078798+00:00"}
{"study_id": 104592, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine how different exercise modes (endurance vs. endurance-strength) affect liver function markers, including alanine aminotransferase (ALT), in women with abdominal obesity.", "results_summary": "Endurance-strength exercise (group B) led to greater improvements in liver function, with significant decreases in ALT and AST levels, compared to endurance exercise (group A). Both groups showed significant reductions in GGT levels, but no changes were observed in ALP activity or bilirubin levels.", "population_specificity": "44 women with abdominal obesity", "effective_dosage": "Not applicable (exercise intervention)", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.303298+00:00"}
{"study_id": 104593, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were reviewing the conceptual background and preclinical evidence for optogenetics as a tool for stroke recovery, not specifically studying Alanine.", "results_summary": "The abstract does not mention any findings related to Alanine, focusing instead on optogenetics and its potential in stroke recovery.", "population_specificity": "Not specified (preclinical and translational considerations in stroke recovery).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.548317+00:00"}
{"study_id": 104591, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the preventive effects of oral lansoprazole on acute exacerbation of COPD, with alanine aminotransferase levels monitored as part of liver function assessment.", "results_summary": "The study found that alanine aminotransferase levels were statistically different in the group not receiving lansoprazole therapy compared to the other groups, but the abstract does not specify the clinical significance or direction of this change.", "population_specificity": "Patients with COPD in groups C and D in the stable phase, stratified by gastroesophageal reflux and lansoprazole therapy status.", "effective_dosage": "Not specified for alanine.", "study_duration": "12-month follow-up period.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.619546+00:00"}
{"study_id": 104594, "supplement_id": 863, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness and safety of peginterferon plus Chinese herbal therapies versus peginterferon alone in treating HBeAg-positive chronic hepatitis B (CHB) patients, including effects on alanine transaminase normalization.", "results_summary": "Combined peginterferon and Chinese herbal therapies outperformed peginterferon alone in achieving higher HBV DNA and HBeAg clearance rates, HBeAg seroconversion, improved liver fibrosis biomarkers, fewer relapses, fewer adverse events, and faster alanine transaminase normalization.", "population_specificity": "HBeAg-positive chronic hepatitis B (CHB) patients (624 participants across 8 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:22.545647+00:00"}
{"study_id": 104595, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study examined the metabolic consequences, including changes in alanine aminotransferase levels, associated with risperidone monotherapy in children with autism spectrum disorder (ASD).", "results_summary": "The study found significant increases in alanine aminotransferase (ALT) levels (p = .01) from baseline to week 16, indicating potential liver stress, alongside other metabolic changes like insulin resistance and weight gain.", "population_specificity": "124 children (mean age 6.9 \u00b1 2.35 years; 105 boys, 19 girls) with ASD and serious behavioral problems.", "effective_dosage": "Not specified for alanine (study focused on risperidone).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:25.108907+00:00"}
{"study_id": 104596, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare metabolite differences, including alanine, between newborns with intrauterine growth restriction (IUGR) and appropriate-for-gestational-age (AGA) newborns to explore metabolic mechanisms of IUGR-related tissue damage.", "results_summary": "Alanine levels differed significantly based on birth weight and gestational age, with lower birth weight IUGR infants showing greater metabolic abnormalities, including altered alanine levels. The study suggests alanine metabolism is disrupted in IUGR infants, particularly those with birth weight below the 3rd percentile.", "population_specificity": "60 IUGR and 60 AGA newborns hospitalized in a neonatal intensive care unit.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:25.420350+00:00"}
{"study_id": 104597, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "To compare the protective efficacy of recombinant adenovirus containing Hyper-IL-6 and HGF (Ad-HGF-HIL-6) versus Ad-HIL-6 or Ad-HGF alone in rats with acute-on-chronic liver failure (ACLF).", "results_summary": "The study found that Ad-HGF-HIL-6 treatment significantly reduced liver damage markers (e.g., alanine aminotransferase, HMGB1, TNF-\u03b1) and apoptotic activity while increasing cell proliferation markers (e.g., Ki67, Bcl-2/Bax ratio), with more pronounced effects than Ad-HIL-6 or Ad-HGF alone. No significant side effects were observed.", "population_specificity": "Rats with acute-on-chronic liver failure (ACLF).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.097909+00:00"}
{"study_id": 104599, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to understand the reasons for the disparity in mortality outcomes between Finnish and other patients treated with levosimendan or dobutamine in the SURVIVE trial, focusing on factors like alanine transferase levels among others.", "results_summary": "The study found that baseline variables, including alanine transferase levels, predicted survival in the whole SURVIVE trial population, but the abstract does not detail specific effects of alanine itself. Finnish patients showed lower mortality with levosimendan, associated with factors like higher \u03b2-blocker use and earlier treatment initiation.", "population_specificity": "1327 acute heart failure patients, with a focus on a Finnish sub-population of 95 patients.", "effective_dosage": "Not specified", "study_duration": "180-day follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.465307+00:00"}
{"study_id": 104600, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of telbivudine (TBV) versus lamivudine (LAM) and entecavir (ETV) in treating decompensated HBV-related cirrhosis, including effects on alanine aminotransferase (ALT) normalization.", "results_summary": "TBV showed comparable efficacy to ETV and LAM in virological response, ALT normalization, and clinical outcomes, with similar safety profiles and complication rates. However, TBV had a higher virological breakthrough rate than ETV but lower than LAM.", "population_specificity": "130 treatment-na\u00efve patients with HBV-related decompensated cirrhosis.", "effective_dosage": "Not specified", "study_duration": "24 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.680585+00:00"}
{"study_id": 104598, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the cost-effectiveness of adding antiviral therapy to sorafenib in patients with advanced HBV-related hepatocellular carcinoma (HCC), focusing on outcomes like quality-adjusted life years (QALYs).", "results_summary": "The study found that adding antiviral therapy to sorafenib increased effectiveness (0.68 QALYs vs. 0.42 QALYs) at a higher cost ($25,026.04 vs. $20,249.64), with an incremental cost-effectiveness ratio (ICER) of $18,370.77/QALY, making it cost-effective in China. Subgroup analyses showed varying ICERs based on HBV-DNA load, cirrhosis status, and liver enzyme levels.", "population_specificity": "Patients with advanced HBV-related hepatocellular carcinoma (HCC) in China.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.696742+00:00"}
{"study_id": 104590, "supplement_id": 863, "safety_score": "85", "efficacy_score": 30, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy of sitagliptin versus placebo in reducing liver fat (measured by MRI-PDFF) in patients with NAFLD and prediabetes or early diabetes.", "results_summary": "Sitagliptin was not significantly better than placebo in reducing liver fat or improving liver fibrosis. Both groups showed no significant changes in liver fat or other metabolic markers, though MRI-PDFF and MRS demonstrated strong internal validity.", "population_specificity": "50 NAFLD patients with prediabetes or early diabetes.", "effective_dosage": "100mg/day orally.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:28.733131+00:00"}
{"study_id": 104601, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of buthionine sulfoximine (BSO) combined with melphalan in treating recurrent/resistant high-risk neuroblastoma, with alanine aminotransferase levels monitored as part of toxicity assessment.", "results_summary": "The study found that BSO-melphalan was tolerable with stem cell support, showing some activity in recurrent/refractory neuroblastoma, including partial and mixed responses. Melphalan pharmacokinetics with BSO were similar to melphalan alone, but Cmax levels were below preclinical activity thresholds.", "population_specificity": "Patients with recurrent/resistant high-risk neuroblastoma.", "effective_dosage": "BSO (3 gram/m\u00b2 bolus, then 24 grams/m\u00b2/day infusion days -4 to -2) with escalating doses of melphalan (20-125 mg/m\u00b2 days -3 and -2).", "study_duration": "BSO administered over 3 days (days -4 to -2), melphalan over 2 days (days -3 and -2).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:33.673091+00:00"}
{"study_id": 104603, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether alanine aminotransferase (ALT) or \u03b3-glutamyl transferase (GGT) levels predict mortality in type 2 diabetes and to examine possible mechanisms.", "results_summary": "Lower ALT levels were associated with a higher risk of cardiovascular death, while elevated GGT levels were linked to higher risks of death from cardiovascular disease, cancer, and non-cancer/non-cardiovascular causes. The relationship for ALT persisted after adjusting for frailty measures but was attenuated by elevated hsCRP.", "population_specificity": "Individuals with type 2 diabetes from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.", "effective_dosage": "Not specified", "study_duration": "5 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:34.449838+00:00"}
{"study_id": 104602, "supplement_id": 863, "safety_score": "30", "efficacy_score": 10, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, efficacy, and pharmacogenetic characteristics of clofarabine in Japanese pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).", "results_summary": "The study found that clofarabine at 52 mg/m\u00b2/day had a tolerable safety profile but no complete or partial remission was observed. Adverse events included increased alanine aminotransferase and other hematologic toxicities.", "population_specificity": "Japanese pediatric patients with relapsed/refractory ALL (n=7).", "effective_dosage": "Cohort 1: 30 mg/m\u00b2/day for 5 days, then 52 mg/m\u00b2/day for 5 days in subsequent cycles; Cohort 2: 52 mg/m\u00b2/day for 5 days.", "study_duration": "Up to six cycles (exact duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.102833+00:00"}
{"study_id": 104606, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between WNK1 and STK39 gene variants (involving alanine-related kinase pathways) and blood pressure/hypertension.", "results_summary": "The study found that specific genotypes (rs3754777 in STK39 and rs1468326 in WNK1) were significantly associated with higher hypertension risk and elevated systolic blood pressure, suggesting a role for these genes in blood pressure regulation.", "population_specificity": "779 Caucasian hypertensive patients and 906 normotensive controls from Belgium.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.535049+00:00"}
{"study_id": 104607, "supplement_id": 863, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety of intravenous catumaxomab, including its effects on liver enzymes like alanine aminotransferase, in patients with EpCAM-positive tumors.", "results_summary": "The study found that catumaxomab caused dose-dependent hepatitis, marked by elevated liver enzymes (including alanine aminotransferase), bilirubin, and inflammatory markers, leading to fatal acute liver failure in one patient. The off-target hepatotoxicity involved T-cell-mediated cytotoxicity and Kupffer cell activation, independent of EpCAM expression in hepatocytes.", "population_specificity": "Patients with EpCAM-positive tumors.", "effective_dosage": "10\u03bcg (fatal dose mentioned; other doses not specified).", "study_duration": "Not specified (study terminated early).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:36.578147+00:00"}
{"study_id": 104605, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate potential relationships between direct-acting antiviral (DAA) exposures (ombitasvir/paritaprevir/ritonavir) and laboratory abnormalities or adverse events, including peripheral edema, in Japanese patients with hepatitis C virus subgenotype 1b infection.", "results_summary": "The study found no apparent relationship between DAA exposures and peripheral edema, and only a shallow relationship between paritaprevir exposure and total bilirubin elevation. DAA exposures were weakly associated with hemoglobin decrease but not with alanine aminotransferase or aspartate aminotransferase elevations.", "population_specificity": "Japanese adults with hepatitis C virus subgenotype 1b infection, including noncirrhotic and compensated cirrhotic patients.", "effective_dosage": "Ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily.", "study_duration": "12 weeks.", "interactions": "Concomitant administration of calcium channel blockers was associated with peripheral edema events.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.789786+00:00"}
{"study_id": 104604, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to assess the tolerability, pharmacokinetic, and pharmacodynamic properties of PF-06260414, a selective androgen receptor modulator, in healthy subjects, including ethnic differences between Japanese and Western populations.", "results_summary": "PF-06260414 was well tolerated with no serious adverse events, though some subjects experienced increased alanine aminotransferase and headache. The compound showed fast absorption, dose proportionality, and significant modulation of HPG axis hormones, particularly in the 100-mg BID regimen.", "population_specificity": "Healthy subjects, including a Japanese cohort and Western subjects.", "effective_dosage": "SAD (1-400 mg), MAD (3-100 mg BID), 60 mg once-daily, and 30 mg BID for Japanese subjects.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.853805+00:00"}
{"study_id": 104608, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and safety of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer, not specifically to evaluate Alanine.", "results_summary": "The study found that S-1 improved relapse-free survival compared to UFT, with 5-year RFS rates of 66.4% vs. 61.7%. Adverse events included increased alanine aminotransferase in the UFT arm (2.3%) but no specific focus on Alanine's effects.", "population_specificity": "Patients aged 20-80 with curatively resected stage II/III rectal cancer in Japan.", "effective_dosage": "Not applicable (study focused on chemotherapy regimens, not Alanine supplementation).", "study_duration": "1 year of adjuvant chemotherapy.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.991709+00:00"}
{"study_id": 104609, "supplement_id": 863, "safety_score": "80", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and potential biomarkers of muscle damage related to SMT C1100 (a utrophin modulator) in pediatric DMD patients.", "results_summary": "SMT C1100 was well tolerated with mostly mild adverse events, though some patients experienced pain or moderate psychiatric effects. Plasma concentrations showed high variability and were lower than in healthy volunteers, while muscle damage biomarkers generally decreased with dosing.", "population_specificity": "Pediatric patients with Duchenne muscular dystrophy (DMD).", "effective_dosage": "50 mg/kg or 100 mg/kg, administered once or twice daily (bid) or three times daily (tid) depending on the group.", "study_duration": "11 days (with dosing on Days 1-11).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:42.638315+00:00"}
{"study_id": 104611, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify factors affecting the efficacy of corticosteroid therapy in managing HELLP syndrome, including changes in alanine transaminase levels.", "results_summary": "Corticosteroid therapy significantly improved alanine transaminase levels in HELLP syndrome patients, with higher doses associated with greater declines. Lower baseline platelet count and urinary output predicted greater improvements in related markers.", "population_specificity": "HELLP syndrome patients (778 participants across 22 studies).", "effective_dosage": "High-dose corticosteroid therapy (specific dosage not detailed).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:43.097481+00:00"}
{"study_id": 104610, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were evaluating the effect and safety of acupuncture therapy compared to medication (budesonide nasal spray with cetirizine tablets) for moderate to severe allergic rhinitis, with alanine aminotransferase as one of the monitored safety indicators.", "results_summary": "The study found no statistically significant differences in clinical efficacy between acupuncture and medication groups, and alanine aminotransferase levels remained within normal ranges in the acupuncture group.", "population_specificity": "Patients with moderate to severe allergic rhinitis (76 participants, 38 per group).", "effective_dosage": "Not specified for alanine.", "study_duration": "8 weeks of intervention, with follow-up at 12 weeks post-treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.129939+00:00"}
{"study_id": 104612, "supplement_id": 863, "safety_score": "40", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the incidence of liver enzyme elevations (LEE) in treatment-experienced HIV patients switching from enfuvirtide (ENF) to raltegravir (RAL) and identify risk factors for elevated alanine aminotransferase (ALT).", "results_summary": "The study found a higher incidence of ALT elevation in the RAL arm compared to the ENF arm, though not statistically significant. Tipranavir/ritonavir use and elevated baseline ALT levels were significantly associated with increased risk of ALT elevation.", "population_specificity": "Highly treatment-experienced HIV patients.", "effective_dosage": "Not specified.", "study_duration": "48 weeks.", "interactions": "Tipranavir/ritonavir use was associated with increased risk of ALT elevation.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.382215+00:00"}
{"study_id": 104613, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the potential effects of lifestyle interventions (diet and exercise) and dietary supplements, including alanine-related outcomes, on pediatric NAFLD.", "results_summary": "The study found that lifestyle interventions (diet and exercise) may improve serum alanine aminotransferase activity and liver fat fraction, but no specific dietary approach was superior. Dietary supplements like vitamin E, fish oil, and probiotics showed inconsistent effects.", "population_specificity": "Children with nonalcoholic fatty liver disease (NAFLD), particularly those who are obese.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.517205+00:00"}
{"study_id": 104614, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the influence of chronic hepatitis B infection (CHBI) on the susceptibility to antituberculosis drug-induced liver injury (ATDILI), particularly focusing on alanine aminotransferase levels.", "results_summary": "The meta-analysis found that CHBI significantly increased the risk of ATDILI in standard combination therapy for active TB, with a pooled odds ratio of 2.18. The association was stronger in prospective studies (OR 3.41) but not significant in case-control studies or with isoniazid-only treatment.", "population_specificity": "Patients undergoing anti-TB treatment, including chronic hepatitis B carriers.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:46.060162+00:00"}
{"study_id": 104616, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers investigated whether serum HBsAg levels at the end of entecavir treatment were associated with the risk of relapse in chronic hepatitis B patients.", "results_summary": "The study found that serum HBsAg levels were significantly associated with relapse risk in hepatitis B e antigen-negative patients, with lower HBsAg levels (<10 IU/mL) indicating no relapse.", "population_specificity": "161 consecutive patients with chronic hepatitis B who completed \u22653 years of entecavir therapy.", "effective_dosage": "Not specified", "study_duration": "\u22653 years of entecavir therapy", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:46.533225+00:00"}
{"study_id": 104615, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to investigate the efficacy and safety of luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, in obese diabetic patients, focusing on its effects on glycemic control and body weight.", "results_summary": "Luseogliflozin significantly reduced HbA1c, fasting plasma glucose, and body weight across all BMI groups, with greater weight reduction in higher BMI patients. It also improved metabolic parameters like insulin secretion and blood pressure, with a favorable safety profile.", "population_specificity": "Japanese patients with type 2 diabetes mellitus, stratified by baseline BMI.", "effective_dosage": "2.5 mg daily (or up to 5 mg daily).", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:46.719958+00:00"}
{"study_id": 104617, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate statin-related hepatotoxicity, specifically changes in AST/ALT levels, in Korean outpatients with baseline borderline or normal AST/ALT levels.", "results_summary": "The study found that patients with borderline baseline AST/ALT levels had a significantly higher progression rate to abnormal levels (>\u00d73 UNL) compared to those with normal baseline levels. Pitavastatin was least likely, and fluvastatin most likely, to cause abnormal AST/ALT elevations in patients with borderline baseline levels.", "population_specificity": "Korean outpatients at two large academic teaching hospitals.", "effective_dosage": "Not specified", "study_duration": "First year of statin prescription", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:50.961211+00:00"}
{"study_id": 104618, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers evaluated the effectiveness of early blood purification therapy in improving respiratory function and inflammatory markers in patients with severe acute pancreatitis (SAP) complicated by acute lung injury (ALI), with a focus on alanine aminotransferase levels.", "results_summary": "The study found that early blood purification therapy led to better recovery of respiratory indexes, less pronounced changes in alanine aminotransferase levels, and improved inflammatory markers compared to routine treatment alone. It also reduced MODS and ARDS occurrence.", "population_specificity": "64 patients with SAP complicated by ALI (32 in the control group, 32 in the study group).", "effective_dosage": "Not specified", "study_duration": "72 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:51.511905+00:00"}
{"study_id": 104620, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the incidence and outcomes of alanine aminotransferase (ALT) flares during long-term entecavir (ETV) therapy in chronic hepatitis B (CHB) patients.", "results_summary": "The study found a low cumulative incidence of ALT flares (6.3% at year 5) during ETV therapy, with host-induced flares associated with biochemical remission and seroconversions, while virus-induced flares were linked to resistance and non-compliance.", "population_specificity": "Chronic hepatitis B (CHB) patients treated with ETV monotherapy from 11 European centers.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median of 3.5 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.137022+00:00"}
{"study_id": 104622, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of pembrolizumab in Japanese patients with advanced solid tumors, not specifically Alanine.", "results_summary": "The study found pembrolizumab was well tolerated with mostly mild to moderate adverse events, including AST/ALT elevations, and showed encouraging antitumor activity in melanoma and NSCLC. Alanine was not the focus of the study.", "population_specificity": "Japanese patients with advanced solid tumors", "effective_dosage": "Pembrolizumab at 2 or 10 mg/kg every 2 weeks", "study_duration": "Until disease progression or unacceptable toxicity", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.980050+00:00"}
{"study_id": 104621, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the effectiveness and safety of teriflunomide (a pyrimidine synthesis inhibitor) as a disease-modifying therapy for relapsing-remitting multiple sclerosis, including its impact on relapse rates and disability progression.", "results_summary": "Teriflunomide at 7 mg/day and 14 mg/day reduced relapse rates over one and two years compared to placebo, with the 14 mg/day dose also reducing disability progression. Adverse effects included elevated alanine aminotransferase, diarrhea, nausea, and hematologic changes, mostly mild-to-moderate and dose-related.", "population_specificity": "Adults with relapsing forms of multiple sclerosis and an Expanded Disability Status Scale score < 5.5.", "effective_dosage": "7 mg/day and 14 mg/day.", "study_duration": "One to two years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.090656+00:00"}
{"study_id": 104623, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the therapeutic potential and short-term safety of chloroquine (CQ) in patients with chronic HCV genotype 1, focusing on its impact on HCV RNA load and plasma alanine transaminase (ALT) levels.", "results_summary": "CQ treatment significantly decreased HCV RNA levels by week 8 and normalized ALT levels during treatment, but these effects were lost after treatment cessation. The study suggests CQ may be a safe short-term option for HCV non-responders.", "population_specificity": "Ten non-responders to previous antiviral treatment for chronic HCV genotype 1.", "effective_dosage": "150 mg daily", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:55.007365+00:00"}
{"study_id": 104619, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of daclatasvir plus asunaprevir (DCV + ASV) in Asian patients with hepatitis C virus genotype 1b infection, not specifically Alanine.", "results_summary": "The study found high sustained virological response rates (SVR12) in Asian patients treated with DCV + ASV, comparable to non-Asian patients, with low incidence of serious adverse events. Elevated alanine aminotransferase was noted in two patients, but both achieved SVR12.", "population_specificity": "Asian patients (Korean, Taiwanese, others) with HCV genotype 1b infection, including treatment-naive, ineligible/intolerant, and non-responder subgroups.", "effective_dosage": "DCV (60 mg once daily) plus ASV (100 mg twice daily).", "study_duration": "12 weeks for initial treatment, with an additional 12 weeks for continued treatment in some groups; 24 weeks for non-responders and ineligible/intolerant patients.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:55.405052+00:00"}
{"study_id": 104624, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and clinical activity of Trametinib, a MEK1/MEK2 inhibitor, in patients with relapsed/refractory leukemias, including its effects on alanine aminotransferase levels.", "results_summary": "The study found that increased alanine aminotransferase levels were among the most commonly reported treatment-related adverse events, but the abstract does not provide specific details on Alanine's effects. Trametinib showed preferential activity in RAS-mutated myeloid malignancies.", "population_specificity": "Patients with relapsed/refractory leukemias, including AML, MDS, and CMML, with or without RAS mutations.", "effective_dosage": "2 mg orally daily (for Trametinib).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:55.633426+00:00"}
{"study_id": 104625, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate biochemical parameters, including alanine aminotransferase (ALT), in pregnant women with preeclampsia and IUGR compared to healthy pregnant women.", "results_summary": "The study found statistically significant differences in serum ALT levels between women with preeclampsia and IUGR and healthy pregnant women, suggesting ALT may be a marker for perinatal complications due to hypoxia.", "population_specificity": "Pregnant women (60 with preeclampsia and IUGR, 60 healthy controls).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:58.734782+00:00"}
{"study_id": 104626, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the nutritional benefits and safety of olive oil- and SMOF-based lipid emulsions (LEs) versus soybean oil-based LEs, including their effects on liver function indicators such as alanine transaminase.", "results_summary": "The meta-analysis found that SMOF-based LEs were associated with higher plasma concentrations of beneficial nutrients (\u03b1-tocopherol, oleic acid, \u03c9-3 PUFAs) and lower \u03c9-6 PUFAs, while showing similar liver function effects to soybean oil-based LEs. Alanine transaminase levels were not significantly different between the LE types.", "population_specificity": "Patients receiving parenteral nutrition (specific population not detailed in abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:00.827640+00:00"}
{"study_id": 104628, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to investigate the metabolic pathways involved in bladder cancer, including the role of alanine as a byproduct of altered glycolysis.", "results_summary": "The study found that bladder cancer cells exhibit increased glycolytic flux, leading to overproduction of alanine and lactate, which supports tumor growth and proliferation. Alanine is identified as a metabolic byproduct rather than a therapeutic target in this context.", "population_specificity": "Bladder cancer cells (in vitro or preclinical model, not specified).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:01.444211+00:00"}
{"study_id": 104629, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy of 19 noninvasive scores, including those involving alanine transaminase (ALT), in predicting liver fibrosis stages in chronic hepatitis C patients.", "results_summary": "King's score showed the highest predictive accuracy for significant and advanced fibrosis, while APRI and FIB-4 were most accurate for cirrhosis. The derived study score also demonstrated high predictive accuracy for cirrhosis.", "population_specificity": "1602 patients with chronic hepatitis C (mean age 41.8\u00b19.6 years, 1365 men).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:03.251658+00:00"}
{"study_id": 104632, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare therapeutic outcomes between HCV patients with normal and elevated ALT levels treated with IFN-based therapies.", "results_summary": "The study found comparable sustained virologic response rates between HCV patients with normal and elevated ALT levels, but higher HCC development in the elevated ALT group. Multivariate analysis identified factors like younger age, female gender, and non-cirrhosis as favorable for SVR, while older age and cirrhosis increased HCC risk.", "population_specificity": "3241 HCV patients in Taiwan (186 with normal ALT, 3055 with elevated ALT).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:03.621376+00:00"}
{"study_id": 104631, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 22, "quality_score": 75, "study_goal": "The researchers aimed to determine the clinical significance of anti-smooth muscle autoantibody (SMA) in patients with normal or raised alanine aminotransferase (ALT) levels and its predictive value for Autoimmune Hepatitis (AIH).", "results_summary": "The study found that progression to AIH in patients with normal liver function and positive SMA was rare (0.5%), but patients with raised ALT (>55IU/L) had a 22% predictive value for AIH. Most AIH diagnoses (80%) occurred within three months of a positive SMA result.", "population_specificity": "251 consecutive patients with positive tubular or glomerular SMA, including those with normal and raised ALT levels.", "effective_dosage": "Not available", "study_duration": "12-year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:04.540703+00:00"}
{"study_id": 104630, "supplement_id": 863, "safety_score": "60", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to assess the whole-body activity and intracranial efficacy of ceritinib, an ALK inhibitor, in patients with ALK-rearranged NSCLC, including those pretreated or naive to ALK inhibitors.", "results_summary": "Ceritinib showed durable whole-body responses, with an overall response rate of 72% in ALK inhibitor-naive patients and 56% in pretreated patients, along with intracranial disease control in 79% and 65% of patients, respectively. However, common adverse events included increased alanine aminotransferase (30%) and aspartate aminotransferase (10%), as well as grade 3-4 diarrhea and nausea (6% each).", "population_specificity": "Patients aged 18+ with ALK-rearranged locally advanced or metastatic NSCLC, including those with brain metastases.", "effective_dosage": "750 mg/day orally.", "study_duration": "Median follow-up was 11.1 months (IQR 6.7-15.2).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:05.706919+00:00"}
{"study_id": 104634, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the safety and efficacy of a chemotherapy regimen (PPB) for lung adenocarcinoma.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with untreated, advanced lung adenocarcinomas.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:07.696959+00:00"}
{"study_id": 104633, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the best noninvasive test for predicting advanced liver disease in patients with severe obesity, focusing on indices like the aspartate aminotransferase/alanine aminotransferase ratio (AAR).", "results_summary": "The APRI index was the best predictor of advanced liver disease in patients with severe obesity, with high sensitivity (1.0) and specificity (.97). Other indices like AAR, AP, CDS, and HALT-C also showed varying levels of predictive accuracy.", "population_specificity": "Patients with severe obesity undergoing bariatric surgery (699 total, 131 with liver biopsies).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:08.490935+00:00"}
{"study_id": 104637, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it evaluates the efficacy and safety of atezolizumab in patients with metastatic urothelial carcinoma.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with metastatic urothelial carcinoma who progressed after platinum-based chemotherapy.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:09.956593+00:00"}
{"study_id": 104635, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of hyperbaric oxygen therapy on recovery markers, including alanine aminotransferase (ALT), in jiu-jitsu athletes.", "results_summary": "The study found no significant effect of hyperbaric oxygen therapy on ALT levels or other cellular damage markers, indicating no influence on recovery. However, perceived recovery was higher in the hyperbaric oxygen therapy group.", "population_specificity": "Eleven experienced Brazilian jiu-jitsu athletes.", "effective_dosage": "Not specified (hyperbaric oxygen therapy duration: 2 hours).", "study_duration": "Two sessions with a 7-day washout period.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:10.142747+00:00"}
{"study_id": 104636, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, antiviral activity, and pharmacokinetics of GS-9857 in patients with chronic HCV genotype 1-4 infection.", "results_summary": "GS-9857 was well tolerated with mild to moderate adverse events, demonstrated potent antiviral activity (\u22653 log10 IU/mL reduction in HCV RNA), and exhibited linear pharmacokinetics supporting once-daily dosing.", "population_specificity": "Patients with chronic HCV genotype 1-4 infection.", "effective_dosage": "50 to 300 mg once daily.", "study_duration": "3 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:10.762648+00:00"}
{"study_id": 104627, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of gefitinib for treating metastatic NSCLC with specific EGFR mutations, not Alanine.", "results_summary": "The study found gefitinib had a 50% ORR and median DoR of 6.0 months, with common adverse reactions including increased alanine aminotransferase. It did not assess Alanine's effects.", "population_specificity": "Patients with metastatic EGFR mutation-positive NSCLC.", "effective_dosage": "Not applicable (study focused on gefitinib, not Alanine).", "study_duration": "Until disease progression or intolerable toxicity.", "interactions": "None mentioned (for Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:12.019184+00:00"}
